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“Life should not be a journey to the grave with the intention of arriving safely in a pretty and well 
preserved body, but rather to skid in broadside in a cloud of smoke, thoroughly used up, totally worn 
out, and loudly proclaiming "Wow! What a Ride!” ” – Hunter S. Thompson  
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Abstract 
Asthma is a complex disease characterized by the interaction of several different cell 
types with chronic tissue remodeling that leads to the observed symptoms of reversible airflow 
obstruction and airway hyper-responsiveness (AHR). 
Although several advances have been made in the characterization of this disease, no 
viable treatment has been created so far. Since the activation of the hypoxia response 
pathway during the asthmatic response aggravates the outcome of this disease, the 
manipulation of this pathway emerges as an attractive candidate for novel therapy 
development. 
The cell type specific role of the hypoxia-inducible factor (HIF) pathway during the 
asthmatic response is yet to be described. This work was therefore conducted with the 
purpose of investigating the role of the oxygen sensors prolyl hydroxylase domains (PHDs) in 
the T cell compartment as well as in the myeloid compartment during allergic asthma in mice. 
Ovalbumin (OVA) and house dust mite (HDM) were used as antigens to induce the asthmatic 
phenotype.   
PHD2 was found to have a protective role in the T cells during asthma, as mucus 
secretion and vascular remodeling were observed to be increased upon deletion of this 
protein.  
Although deletion of PHD2 in the myeloid compartment did not seem to affect asthma 
development, combined deletion with PHD3 resulted in higher cell infiltration in the 
bronchoalveolar lavage fluid (BALF) upon asthma, with a marked influx of CD4+ T cells and 
eosinophils.  
This work has thus described for the first time a protective role of PHD2 in the T cells 
during asthma, indicating also a possible compensatory role of PHD3 in the myeloid 
compartment in the control of this disease. Further research is required in the characterization 
of the role of these proteins in the immune cells involved in the asthmatic outcome, hopefully 
leading to new ways to attenuate the symptoms of this disease. 
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Introduction 
 
Asthma is a chronic inflammatory disease that affects more than 300 million people, 
leading to the death of approximately 25.000 people per year worldwide1. The prevalence of 
this disease has been increasing globally during the second half of the 20th century, especially 
in economically developed countries, making it the most common chronic lung disease 
worldwide2,3. This increase has been associated to environmental aspects such as air pollution, 
eating and hygienic habits and drugs, but no single cause has been identified4.  
Asthmatic individuals tend to be more susceptible to these stimuli due to pre-existing 
atopy, a predisposition to developing certain allergic hypersensitivity reactions5. Other risk 
factors involve specific genetic variations in the regulators of type 2 inflammation, but there 
are also less understood vulnerabilities that could be associated with the increase of asthmatic 
cases5. 
The first symptoms of asthma usually appear during childhood, when the patients 
have mild to sporadic episodes of airway obstruction3. These are triggered in vulnerable 
individuals by exposure to virus or airborne pollutants that lead to the activation of the 
epithelium5. The aberrant immune responses to stimuli are established when the immune 
system is still plastic, which may lead to persistent changes in cell behavior and, consequently, 
asthma endurance throughout the whole life5. 
Asthma can also be developed later in life, being the age of onset a crucial factor in 
disease phenotype and development3. Early-onset asthma is associated with a more allergic 
phenotype, whereas late-onset asthma is associated with high eosinophil infiltration and 
inflammation and, generally, fewer allergies3. These patients reveal more severe airflow 
obstruction and are more prone to exacerbations4. 
Asthma is generally characterized as a T helper (Th)2-mediated condition3. This disease 
involves the activation of an array of inflammatory cells affecting the lower airways. Besides 
the T cells, the major mediators of the allergic response observed in asthma are the dendritic 
cells (DCs), eosinophils and mast cells2, approached in more detail below. 
The interaction of the aforementioned cells induces the symptoms of asthma, which 
can range from mild wheezing and cough to severe respiratory distress and even respiratory 
failure6. 
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During the allergic inflammation that occurs in asthma, a hypoxic environment is 
created. Cells respond to this shortage of O2 through the activation of the hypoxia response 
pathway, which perpetuates the highly pro-inflammatory response and consequent 
aggravation of the disease outcome7,8. 
Although the importance of this hypoxic environment in asthma is widely accepted7, 
the role of the hypoxia response pathways’ activation in the different immune cells involved in 
asthma is yet to be described. As myeloid and CD4+ T cells play an important role in the 
pathogenesis of this disease, particularly the Th2 subset; the influence of this pathway in these 
cells’ behavior represents a major cornerstone in the comprehension of this disease. 
Modulators of the hypoxic response are being considered as possible therapies for 
diseases such as cancer9, as in this disease the activity of this pathway is also augmented10. 
Further knowledge regarding the role of the hypoxia response mediators in the inflammatory 
cells of asthma may enable the generation of therapies based on similar principles. 
 
 
1. Hypoxia 
Animals have developed mechanisms that allow them to cope with hypoxia, a 
shortage in the oxygen level11. These allow the body to detect, adjust and react to different 
oxygen concentrations and are finely tuned at organ, tissue and cellular levels12. 
The transcriptional response to hypoxia is mediated by the HIF family. The proteins 
that constitute this family are heterodimeric, containing an α and a β subunit11. HIF1α, HIF2α 
and HIF3α are similar in structure and function. HIF1α is expressed in the majority of cell 
populations, as is HIF1β; whereas HIF2α/3α and HIF2β/3a are only expressed in a limited 
variety of tissues8. The regulatory complex is comprised of one of the -α subunits bound to 
HIFβ. The β subunits are constitutively expressed, being the HIF proteins regulated by post-
transcriptional modifications on their -α subunits11 (Figure 1). 
Regulation of the HIF activity is mediated by a class of enzymes known as PHDs. Under 
normoxic conditions, the PHDs hydroxylate HIFα in specific proline domains, allowing its 
recognition and subsequent ubiquitination by the Von Hippel–Lindau protein (VHL). This leads 
to the proteasomal degradation of the HIFα subunit and, consequently, inactivation of the HIF 
protein13,14. 
As PHDs require O2, iron, ascorbate and 2-oxoglutarate to exert their functions
15, 
under hypoxic conditions they are rendered non-functional and HIFα is stabilized, translocates 
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to the nucleus and binds to the HIFβ subunit. The formed heterodimer binds to hypoxic 
response element (HRE)-containing promoter regions, inducing the transcription of genes 
involved in cellular functions such as cell survival and proliferation, apoptosis, glucose 
metabolism and angiogenesis11,14,16.  
Three PHD isoforms have been described - PHD1, PHD2 and PHD3 - and all are capable 
of hydroxylating HIFα.12, 15 However, PHD2 appears to be the major regulator of the hypoxic 
response17, as elimination of this protein in vitro is sufficient to induce HIFα and systemic 
deletion in genetically engineered mice leads to embryonic lethality, an outcome not observed 
for embryos lacking either PHD1 or PHD318. Expression of each PHD family member is 
distributed in distinct tissues, suggesting that these isoforms have distinct functions. In fact, 
each isoform has a different affinity for the inhibition of particular HIFα subunits; PHD2 has a 
stronger substrate preference for HIF1α, whereas PHD3 degrades preferentially HIF2α under 
hypoxia12.  
PHD3 is itself a target of HIF1α and its induction under hypoxic conditions leads to the 
negative regulation of HIF2α15. This feedback mechanism suppresses HIF activation under 
continued hypoxia19, maintaining a tight balance between the activation of the 
aforementioned transcription factors20. 
The complex network of regulation of the hypoxic response plays a crucial role in 
several physiological as well as pathological processes. Therefore, the differential inhibition of 
PHDs has the potential to alter the characteristics of HIF activation in a selective manner and 
thus modulate these responses. 
 
Figure 1 Molecular mechanism of the hypoxia response pathway. Adapted from Eltzschig et al, 2014.
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1.1. Hypoxia in Asthma 
Inflammation and limited oxygen accessibility are hallmarks of asthma and other 
immunological responses to tissue damage16. 
Bronchial biopsies of asthmatic patients reveal increased activation of the hypoxia 
response pathway8. The activation of the HIF1α subunit has a pro-inflammatory connotation 
and leads to the activation of genes such as vascular endothelial growth factor (VEGF), which 
are implicated in airway remodeling. This pathway has also been associated with increased 
collagen synthesis and fibrosis7.  
Several studies have found increased levels of both HIF1α and PHD2 in animal models 
of asthma7,8. Using the PHD2 inhibitor ethyl 3,4-dihydroxybenzoic acid (DHB), an oxoglutarate 
analogue, Ahmad et al. observed a DHB dose-dependent increase of AHR in a mouse model of 
asthma, associated with an increased cell infiltration, mucus production and collagen 
deposition in the basal membrane of the epithelium7. 
Using a non-specific HIF inhibitor, Huerta-Yepez et al. have reported that the inhibition 
of this pathway reduced the allergic inflammation and lung remodeling in an OVA-triggered 
mouse model21. This group was also able to demonstrate that exposure to allergen in 
asthmatic patients leads to upregulated expression of HIF1α and VEGF8. To support these 
findings, recent work described that the systemic silencing of PHD2, the most important 
oxygen sensor, leads to the exacerbation of the asthmatic response7.  
However, the role of the hypoxia-inducible pathway in particular immune cells 
involved in the pathogenesis of the disease is yet to be fully understood. Toussaint et al. 
described a protective role of HIF1α through the immunoregulation of the asthmatic response 
by the macrophages in the lung22. Their work showed a positive regulation of HIF1α in the 
production of interleukin (IL)-10 by the interstitial macrophages (IMs) in the lung, with 
consequent inhibition of DC activation. This apparent contradictory result demonstrates the 
importance of the cell-specific modulation of the hypoxic response in the outcome of the 
disease. As inhibitors of PHD2 are being considered as drugs for several conditions, the role of 
this protein in asthmatic disease needs to be further analyzed9. 
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2. Asthma Pathophysiology 
Asthma is characterized by several alterations in the airways including exacerbated 
mucus production, shedding of epithelial cells, thickening of the bronchial walls, artery 
remodeling and proliferation and smooth muscle hyperplasia2,3. These changes lead to 
reversible airflow obstruction (dyspnea), AHR and sputum production6. 
Since 2008, the biological heterogeneity of asthma has been approached considering 
endotypes of this disease; disease subtypes with different functional mechanisms5. Until now, 
only one endotype has been described, based on the level of type 2 inflammation5.  
Type 2 inflammation is mainly regulated by Th2 cells and characterized by high 
antibody production and eosinophil infiltration5,6. Th2-high asthma patients represent the 
majority of asthmatic individuals and show higher levels of type 2 inflammation in the lung 
than healthy subjects, with high levels of IL-13 and eosinophilia3,23. Contrarily, Th2-low 
asthmatics possess eosinophil levels comparable to the normal healthy reference and are 
modeled by mechanisms yet to be understood5. The individuals that constitute this endotype 
might derive from a variety of endotypes with distinct characteristics that may include airway 
smooth muscle abnormalities, neutrophil infiltration or oxidative stress effects23. 
Nevertheless, both endotypes reveal the same physiological hallmarks of asthma5. 
These pathophysiological changes result in a lower lung capacity6 and in the more severe 
spectrum of asthma the symptoms start overlapping with conditions such as chronic 
obstructive pulmonary disease (COPD)3, leading ultimately to the death of the patient.  
 
 
3. Asthmatic Immune Response 
Asthmatic individuals show a hypersensitivity to airborne allergens triggered by 
immunoglobulin (Ig) E production, with activation of the airway epithelial cells, infiltration of 
immune cells in the lung tissue and remodeling of the epithelium and involving matrix5. 
The clinical phenotype of asthma is very heterogeneous, as the immune response 
involves several cell types. The classical view of this disease consists of a coordinated 
interaction between DCs and CD4+ helper T lymphocytes, leading to the infiltration and 
activation of eosinophils and mast cells2,3 (Figure 2). 
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Although this disease is characterized as a Th2-mediated condition, other 
innate/adaptive pathways are also involved23. 
3.1. Sensitization 
The airway epithelium serves as a barrier to airborne antigens, such as allergens, virus 
and pollutants. This structure is patrolled by immature DCs, which are distributed throughout 
the epithelial basement membrane of the lung, controlling the immune response to inhaled 
antigens24.  
In an asthmatic individual the tight junctions between epithelial cells are loosened, 
leading to the crossing of this barrier of antigens that wouldn’t be harmful for healthy 
individuals but trigger the asthmatic response in susceptible people6. Under these conditions, 
the epithelial cells secrete a variety of mediators such as IL-25 and IL-333 that act as Th2-
instructing signals for the lung DCs24. These regulators induce the augmented production of 
type 2 cytokines that prompt the ensuing events observed in asthma5. 
 
Figure 2 Principal immune pathways involved in the pathogenesis of asthma. The interactions between 
DCs, T cells, eosinophils and mast cells are depicted in the picture, as well as the resulting airway 
alterations. Adapted from Martinez et al, 2013.
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The lung DCs are in this way activated by the airborne antigen through the pattern-
recognition receptors (PRR) on its surface. These cells maturate as they are at the same time 
stimulated by the cytokines produced by the epithelial cells6,24. Therefore, presentation of 
these antigens by the mature DCs leads to Th cells activation and maturation in the lymph 
nodes6. 
3.2. CD4+ T cell Activation 
CD4+ T cells are crucial regulators of the immune response and inflammatory diseases. 
Th cells are activated by DCs presenting processed cognate antigens, which induces their 
subsequent expansion25. 
During this induction, Th cells differentiate into either T helper type 1 (Th1), Th2, (IL-
17)-producing T helper (Th17) and T regulatory (Treg) subsets under the control of lineage-
specifying genes3. Whereas the first is restricted by the Th2 cytokines, Th17 cells can be 
present in considerable amounts in the asthmatic lung, regulating neutrophilic inflammation in 
Th2-low asthmatics. The contribution of these cells in human asthma, however, is not yet 
completely understood6. 
 
Th2 cells differentiate under the regulation of the transcription factor GATA3 and have 
a described role in humoral immunity5. After activation in the lymph nodes, these cells either 
migrate to the B-cell follicle to induce Ig class switching from IgM to IgE or travel back to the 
airway mucosa where they secrete pro-allergic cytokines such as IL-4, IL-5 and IL-136. These 
cytokines, particularly IL-13, have a critical role in driving the key pathological features of this 
disease2,6. 
IL-4 promotes the Ig class switching, upregulation of adhesion molecules in the 
endothelium and eotaxin production. Besides its role in allergic sensitization, this cytokine also 
has a role in the AHR development and Goblet cell metaplasia6. Furthermore, IL-4 stimulates 
the differentiation of Th cells into a Th2 subset5, resulting in a positive feedback loop. 
Th2 cells are also important sources of IL-5 and granulocyte-macrophage colony-
stimulating factor (GM-CSF), both having a role in eosinophil chemotaxis, maturation, survival 
and activation. Therefore, numbers of activated Th2 cells correlate with the number of 
eosinophils in the BALF25. 
IL-13 is extremely important in the induction and maintenance of AHR, tissue 
remodeling and Goblet cell metaplasia6. This cytokine mediates its effects directly on the 
airway epithelial cells through the IL-4Rα at the surface of these cells4. 
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Therefore, the chronic activation of this Th cell subset is sufficient for the induction of 
inflammation and the remodeling observed in the asthmatic lung. 
 
Th1 cells express the T-box transcription factor (T-bet) and secrete IL-2, interferon-γ 
(IFN-γ) and lymphotoxin-α; stimulating type 1 immunity, which is characterized by the 
elevated phagocytic activity5. 
In the T cells from the asthmatic airways the levels of T-bet mRNA are nearly 
undetectable. However, Th1 cells have been identified in the airway of some asthmatic 
patients, showing a possible role for these cells in this disease4. Th1 cells seem to participate in 
delayed-type hypersensivity reactions as this subset inhibits IgE synthesis through the 
secretion of IFN-γ25. 
 
Th17 cells express IL-17A and IL-17F and the transcription factors retinoic acid 
receptor-related orphan receptor-γt (RORγt) and RORα26. This subset appears to play a crucial 
role in neutrophilic inflammation and autoimmunity. The activation of these cells and 
subsequent IL-17 production also contributes to acute AHR, exacerbating the Th2 cell-
mediated eosinophilic inflammation26,27. However, as IL-17 is also produced by other cell types 
such as mast cells, the particular role of this T cell subset still needs to be further studied26. 
 
Treg cells express the transcription factor forkhead box P3 (Foxp3) and are generated 
under the control of mucosal DCs with low expression of the major histocompatibility complex 
(MHC) class II and costimulatory molecules4,28. Most Tregs are generated during the thymic 
negative selection as a mechanism of self-tolerance development. Natural Tregs (nTregs) 
originate after strong T-receptor signaling upon self-antigen presentation by the DCs in the 
thymus during negative selection. This signaling is stronger than the one inducing conventional 
CD4+ T cell commitment, but not enough to induce deletion, and therefore these cells do not 
go into apoptotic death28. 
As tolerance to nonpathogenic foreign antigens is also needed for the healthy function 
of the body, Treg cells can also be induced peripherally. Induced Tregs (iTregs) originate when 
mature, naïve CD4+ T cells encounter antigens in peripheral lymphoid organs29. IL-2, 
transforming growth factor β (TGF-β) and retinoic acid (RA), produced by CD103-expressing 
DCs28,29,30, are crucial factors for the induction of FoxP3 expression in these CD4+ T cells.  
Both nTregs and iTregs contribute to the inhibition of the inflammatory response that 
occurs upon asthmatic triggering, being the reduced or altered function of Treg cells a 
plausible explanation for the inappropriate immune response that occurs in this disease. Tregs 
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have been shown to control the Th2 responses3 and exert their action via direct and indirect 
mechanisms, such as the production of anti-inflammatory cytokines, as IL-10 and TGF-β29, 
expression of inhibitory molecules26 and downregulation of MHC class II in the DCs surface4. 
3.3. B cell Activation and IgE Production 
Under steady state conditions, IgE exists in insignificant levels in the circulation31. 
However, during asthma Th2 activated cells induce the isotype switching of B cells, leading to 
Ig class switching to IgE, with production of this antibody in high concentrations6. This 
induction is mediated by the IL-4 and IL-13 secreted by the Th2 cells31, as well as physical 
interaction between the T and B cells through the CD40/CD40L molecules32.  
IgE interacts with the high-affinity (FcεRI) and low-affinity (FcεRII) Fc receptor for IgE at 
the surface of effector cells. While FcεRI is expressed only in mast cells, FcεRII is present at the 
surface of macrophages, DCs and eosinophils31. 
Through these receptors, IgE mediates several outcomes of the disease. This antibody 
stimulates the antigen presentation by the DCs to the Th cells in the lymph nodes when bound 
to their FcεRII33, being also involved in the stimulation of pro-inflammatory cytokine 
production by the alveolar macrophages (AMs) when interacting with these cells34. IgE also has 
long-lived interactions with eosinophils, inducing their production of leukotrienes and thus 
contributing for the bronchoconstriction observed in the patients23.  
3.4. Macrophage Activation 
Lung macrophages are comprised of cell populations with distinct characteristics 
divided according to their anatomic distribution into AMs and IMs. While the first are 
distributed along the alveolar space, representing the major immune population in the airway 
lumen under steady state conditions, the second are distributed along the interstitial space of 
the lung35.  
AMs represent the first line of defense against allergens and contribute to 
homeostasis through phagocytosis and inhibition of antigen presentation by the DCs with 
consequent inhibition of T cell activation. These cells are able to produce pro- and anti-
inflammatory mediators, as well as IL-12 or IL-10 and IL-13, orienting the immune response 
triggered in the lung36.  
IMs, in turn, have the capacity to inhibit DC maturation and migration to the lymph 
nodes through the production of IL-10, preventing sensitization to airborne antigen. These 
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cells are less abundant than the AMs and have a lower phagocytic capacity comparing to 
these, but have higher antigen-presenting ability34. 
Under asthmatic triggering, however, both macrophage populations are activated by 
the IL-33 released by the damaged epithelium, differentiating into either classically (M1) or 
alternatively (M2) activated macrophages34. Whereas the first are induced upon stimulation of 
their toll-like receptors (TLR) by lipopolysaccharide (LPS) and produce relatively high amounts 
of pro-inflammatory cytokines such as IL-1β, IL-6 and tumor necrosis factor α (TNF-α); the 
latter differentiate under the stimulus of Th2 cytokines such as IL-4 and IL-13, producing IL-13, 
as well as anti-inflammatory cytokines such as IL-10 and TGF-β37. 
Both subsets have detrimental effects in the outcome of the disease. Although M2 
macrophages produce IL-10, a pro-inflammatory cytokine, the production of TGF-β not only 
contributes for the regulation of the asthmatic response, but in high concentrations, induces 
fibrosis in the tissue36,37. The pro-inflammatory cytokines produced by M1 cells modulate the 
constriction of the smooth muscle cells (SMC) and activate eosinophils and fibroblasts, leading 
to the observed AHR and consequent airflow limitation11,12,21,37. 
Although under steady state conditions these cells inhibit the triggering of an allergic 
response, during asthma the inhibitory function of the macrophages in the tissue seems to be 
reduced, giving way to an inflammatory role of these cells in the disease. 
3.5. Eosinophil Recruitment and Function 
Eosinophils are important effector cells in the asthmatic response, comprising a large 
fraction of the cells in the airway lumen during this disease38. These granulocytes are also 
increased in circulation in asthmatic subjects, correlating with symptom scores25,38. 
Eosinophils migrate to the lung in response to the local production of IL-5 and eotaxin 
by the Th2 cells in this tissue. The first is specific for the eosinophils25 and is the main 
pathogenic factor mediating the development of this granulocyte39,40. These cells release pre-
formed mediators like leukotriene C4 (LTC)4, eotaxin, eosinophil cationic protein (ECP), major 
basic protein (MBP) and eosinophil peroxidase (EPO), as well as cytokines such as IL-4 and IL-
1339. 
LTC4 leads to increased vascular permeability and is a strong smooth muscle 
constrictor, representing one of the major targets in asthma therapy25. While ECP induces 
mast cell degranulation and stimulates the mucus secretion in the airway, MBP not only 
activates mast cells but also directly alters smooth muscle contraction contributing to the 
development of AHR39. This basic protein is toxic for the pulmonary epithelial cells, damaging 
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the epithelium and contributing to its stress signaling25. EPO catalyzes the formation of highly 
reactive oxygen species, promoting oxidative stress and cell death by apoptosis39. 
Eosinophils promote the activation and proliferation of antigen-specific memory T cells 
and Th2 polarization through IL-4 production41, being able to activate both naïve and primed T 
cells39.  
3.6. Mast cell Activation 
Mast cells are key effectors in allergic disorders such as asthma. These cells are 
activated by cross-linking to IgE bound to the antigen through their FcεRI2. When activated, 
mast cells degranulate4, secreting preformed inflammatory mediators, such as proteases, 
nucleotides, serotonin and histamine42. These factors induce vasodilation, formation of edema 
and bronchoconstriction2,41. 
These cells also produce IL-4, IL-13 and IL-25, which promotes the Th2-induced 
outcome, contributing to the perpetuation of the Th2 activation4,42.  As many other effector 
cells, like Th2 cells, conduce to the same features of the disease, the relative influence of the 
mast cells to these symptoms remains to be thoroughly explored41. 
3.7. Neutrophil Recruitment 
Some asthmatic individuals show marked neutrophilic inflammation. Neutrophil 
recruitment in these patients occurs through the IL-8 release from the bronchial epithelial 
cells, a cytokine that also prolongs neutrophil survival43. IL-8 production by the epithelial cells 
is stimulated through the IL-17A released by Th17 cells and mast cells27,43. 
These polymorphonuclear cells produce myeloperoxidase and elastase43, which 
presence in the BALF correlates with the degree of bronchial AHR27. Other cytokine produced 
by these cells is oncostatin M that triggers the proliferation of SMC and fibroblasts, promoting 
airway remodeling43. 
It is unclear whether high neutrophil infiltration reflects a different asthma endotype 
or a different stage of severity41. 
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4. Tissue Remodeling 
4.1. Airway Remodeling 
The continued stimulation of the epithelial, SMCs and fibroblastic cells by the 
cytokines produced by the inflammatory cells leads to AHR and remodeling3. 
The airway epithelium usually presents shedding of the ciliated cells, with metaplasia 
and hyperplasia of the Goblet cells, which produce mucus6. The high rates of proliferation of 
these cells lead to the increase of thickness of the airway wall from 10% to 300% of normal4, 
prompting the decrease of the airway luminal diameter. This decrease is manifested in the 
bronchoconstriction observed in the patient. 
The inflammation that occurs in asthma is not enough to lead to the chronic 
remodeling of the lung. However, this damages the epithelium, locking the epithelial cells in a 
repair phenotype, with an increase of the epidermal growth factor receptor (EGFR)6. Epithelial 
cells in this phase produce pro-fibrotic mediators, such as TGF-β and fibroblast growth factor, 
inducing epithelium-mesenchymal interactions3,6. These interactions induce the differentiation 
of fibroblasts surrounding the epithelium into myofibroblasts, which are involved in collagen 
deposition, leading to the increase of the thickness of the basement membrane6. 
Airflow limitation occurs as an outcome of reversible smooth muscle contraction and 
abnormal SMC proliferation. It is yet to be understood whether this phenomenon is due to 
changes in the phenotype of the SMC or caused by mechanical changes in the airway wall6, as 
SMC respond to their mechanical environment3. The increased thickness of the airway smooth 
muscle layer is associated with clinical severity6, being this remodeling the cause of the airway 
narrowing and AHR that characterize the asthmatic condition4. 
4.2. Vascular Remodeling 
The pulmonary vasculature is composed of three layers: adventitia, composed of 
fibroblasts; media, constituted by SMC; and intima, formed by endothelial cells44. During 
vascular remodeling all of these layers are involved. 
A few hours after exposure to hypoxic conditions, the adventitial fibroblasts increase 
their proliferation rate, being this followed, a few days later, by hypertrophy and hyperplasia 
of the medial44 and intima layers45. Vascular remodeling is observed not only for the large 
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arteries, but also arterioles, veins and microvessels, with muscle deposition around previously 
un-muscularized vessels. The origin of these SMC is yet to be characterized45. 
Pulmonary vascular remodeling causes an elevation of the pulmonary resistance45 and 
thus pulmonary hypertension (PH), which is associated with increased morbidity and mortality 
in asthma patients44. 
 
 
5. Murine Models of Asthma 
Animal models allow the better understanding of pathophysiological processes of 
human diseases in ways that would not be possible in a human being and without harming the 
patient. Murine models, especially those using mice, are the most commonly adopted in 
experimental asthma research due to the range of genetically modified strains available24. 
The induced airway abnormalities don’t resemble human asthma in all aspects, since 
asthma does not develop spontaneously in these animals and their airways have different 
structural and biochemical characteristics46. Also, different genetic backgrounds display 
distinct allergic responses, as induction of airway allergy in C57BL/6 mice does not lead to the 
activation and accumulation of mast cells in the lung, contrary to what observed in BALB/c 
mice47,48. Nevertheless, the triggering of asthma in these mice still elicits similar effects as 
those observed in humans, with Th2 cytokine production, Goblet cell hyperplasia, neutrophil 
response followed by eosinophil response, and IgE production49. 
5.1. OVA-induced Model 
The most widely used model involves systemic sensitization with intraperitoneal 
injection of OVA in the Th2-inducing adjuvant aluminium hydroxide (alum), followed by airway 
challenge with this antigen in order to develop the response49. These procedures can vary in 
the dose, frequency of sensitizations and aerosolization and duration of the latter, as well as 
the time point of analysis after the last challenge46. 
Sensitization with OVA can also be done via inhalation, in which an initial nasal 
exposure is used followed by subsequent repeated exposures to induce the allergic airway 
reaction. As OVA alone does not trigger the immune system, this model is dependent on the 
utilization of pathogen-associated patterns (PAMPs) such as bacterial LPS46. 
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Although this protein induces a robust asthmatic response in mice, OVA is seldom 
implicated in human asthma, which led to the development of alternative models using 
human allergens49. 
5.2. HDM-induced Model 
Contrary to the OVA, HDM is a significant source of allergens to humans, inducing 
atopic symptoms in susceptible individuals50. Airborne HDM is contaminated by LPS, an 
agonist of TLR4, having also other TLR agonists in its composition50. The interaction between 
HDM and these receptors in the epithelial cells is enough to initiate the immune response46. 
Therefore, HDM models involve an inhalation only procedure, where the first inhalation is 
succeeded by repetition of this triggering in later periods with variable dosage and duration50. 
 
 
6. Pharmacotherapy 
As the fundamental role of Th2 cells in asthma is well described despite the complexity 
of this disease, most treatments are focused on targeting Th2 cytokines or their receptors3.  
Inhaled corticosteroids are the major drugs used in the treatment of asthma. These improve 
lung function and reduce the symptoms and exacerbations of the disease in patients with high 
Th2 cell counts23, not being very effective in subjects belonging to the Th2-low subtype3. 
Leukotriene antagonists and inhibitors are also used in asthma therapy to block the 
increased vascular permeability and muscle contraction. However, these drugs show no 
advantages for patients with low eosinophil counts2. 
Although the aforementioned drugs are well established for the treatment of asthma, 
several patients don’t respond to them, making their treatment a considerable challenge3. 
Continued efforts are being made to find new treatments. One example is the humanized 
monoclonal antibodies to IgE, currently used as a therapy, which allow the use of lower 
corticosteroid doses2. Antagonists for the major interleukins responsible for the outcomes of 
the asthmatic disease have also been developed, with low efficacy. Whereas anti-IL-5 
antibodies have shown a contribution to the eosinophil reduction in asthmatic patients26,40 
and IL-13 antibodies seem to improve lung function in the developed clinical trials3, IL-4 
antagonists failed to show clinical efficiency6.  
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Aims and Methodology  
Asthma prevalence has been increasing globally, being the most common chronic lung 
disease in the world2,3. The study of the mechanisms involved in the development of this 
disease is therefore expanding, but still much is to be understood. Murine models of airway 
allergy are well established for the study of this disease, as triggering in mice elicits a similar 
outcome to what is observed in humans49. The importance of the hypoxic environment in 
asthma is widely accepted7, but the cell type-specific role of the HIF pathway proteins during 
the asthmatic response is yet to be comprehended. 
With this in mind, this project was developed with the purpose of studying to what 
extent modulation of the hypoxia response in T cells and myeloid cells influences the overall 
outcome of the disease. The studies were conducted in the PHD2 conditional-deficient mouse 
strain targeted in the T cell compartment (CD4:cre-PHD2f/f mice), as well as PHD2 and 
PHD2/PHD3 conditional-deficient mice in the myeloid compartment (LysM:cre-PHD2f/f and 
LysM:cre-PHD2f/f PHD3f/f mice). All mice were crossed back on a C57BL/6N background (>N9). 
OVA and HDM allergy airway models were used to elicit the asthmatic response. 
Hallmarks of asthma were then assessed for all genotypes using several mouse, biochemical 
and histological methods. 
The influence of the hypoxia response pathway activation in either T cells or myeloid 
cells on the inflammatory cell infiltration, mainly eosinophils, in the BALF and the pulmonary 
tissue was investigated, as eosinophilia associates with symptom scores38.  
The characterization of the asthmatic phenotype was one of the major goals of this 
work. As the continued stimulation of the epithelial, smooth muscle and fibroblastic cells 
during the development of asthma induces the remodeling of the lung tissue3, the study of the 
mucus secretion by the epithelial cells, fibrosis and vascular remodeling was crucial to 
comprehend the severity of the disease upon deletion of hypoxia response regulators in the 
aforementioned immune cell populations. 
Furthermore, this project aimed to illustrate the mechanism through which the 
hypoxia response activation in either T cells of myeloid cells contributed to the observed 
phenotype. As the inflammatory milieu in the lung tissue modulates the overall outcome of 
the disease, analysis of the pro-allergic, pro-inflammatory and anti-inflammatory cytokines in 
the lung was performed to further characterize the asthmatic response and therefore gain 
further insight in the role of this pathway in cell activity during asthma.  
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Materials and Methods 
1. Animal Handling 
1.1. Mice Strains 
All mice used in this work were housed at the Medical Theoretical Centre (MTZ) at the 
Medical Faculty (University Hospital Carl-Gustav Carus – University of Technology Dresden, 
Germany), under pathogen-free conditions in individually ventilated cages (IVC) units 
(Techniplast) with ad libitum water and food. Experiments were performed with male and 
female mice between the ages of 8 to 12 weeks. All mouse lines used were born in a normal 
Mendelian distribution at least 9 generations backcrossed to C57BL/6N. All procedures were 
performed in accordance with the facility guidelines on animal welfare while approved by the 
Landesdirektion Dresden, Germany. 
Conditional knockouts (cKO) were based on a Cre-lox system, where the Cre 
recombinase mediated site specific recombination between loxP sites, excising the gene 
region of interest (Figure 3).  
 
Figure 3 Breeding scheme of the mouse strains used in this work. For both the CD4:cre-PHD2
f/f
 (1) and 
LysM:cre-PHD2
f/f
 (2) strains, mice with the cre recombinase in one allele were crossed with mice 
expressing loxP sites encompassing the exon 2 and 3 of PHD2 in both alleles. Two crossing steps were 
required for the generation of these mice, as the first cross leads to, but not only, mice with excision of 
PHD2 in one allele. LysM:cre-PHD2
f/f
 PHD3
f/f
 mice (3) were obtained by the crossing of a heterozygous 
mouse for PHD2 in the myeloid compartment with mice expressing loxP sites flanking the exon 2 of 
PHD3 in both alleles. A second crossing was necessary to obtain homozygous mice lacking both PHD2 
and PHD3 in the myeloid cells. The obtained cKO were analyzed versus their WT littermates; PHD2
f/f
 in 
the case of CD4:cre-PHD2
f/f
 and LysM:cre-PHD2
f/f
, and PHD2
f/f
 PHD3
f/f
 for the LysM:cre-PHD2
f/f
 PHD3
f/f
. 
Only representative outcomes of each crossing are depicted in the figure. 
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CD4:cre+/- and LysM:cre+/- were crossed with mice with loxP sites upstream of exon 2 
and downstream of exon 3 of PHD2 in both alleles. Two crossings allowed the generation of 
both CD4:cre-PHD2f/f (1), lacking PHD2 in the T cells, and LysM:cre-PHD2f/f mice (2), lacking 
PHD2 in the myeloid cells. To generate mice lacking both PHD2 and PHD3 in the myeloid 
compartment, LysM:cre-PHD2f/f PHD3f/f (3), mice obtained from the first crossing of LysM:cre+/- 
with a PHD2f/f mouse were used. These mice were then crossed with PHD3f/f mice, with loxP 
sites flanking the exon 2 of PHD3 in both alleles. The obtained cKO were analyzed versus their 
wild type (WT) littermates; PHD2f/f in the case of CD4:cre-PHD2f/f and LysM:cre-PHD2f/f, and 
PHD2f/f PHD3f/f for the LysM:cre-PHD2f/f PHD3f/f. 
 
1.2. Models of Airway Allergy 
 
5 week OVA-induced asthma model. Sensitization of the mice was performed with 3 
intraperitoneal (IP) injections of 10μg OVA Grade V (Sigma-Aldrich®) and 1mg aluminum 
hydroxide (Sigma-Aldrich®) in 100μL phosphate buffer saline (PBS) (Gibco®) on days 0, 14 and 
21. Triggering of the allergic response in the lung was done with 1% OVA in PBS inhalations on 
the following week (days 27 to 30). Aerosol inhalation was done inside of an IVC for 30 
minutes using a JuniorBOY SX nebulizer (PARI). Mice were sacrificed on day 31 by heart 
extraction after washing and perfusion of the lungs (see below) (Figure 4). 
 
Figure 4 Time frame of the 5 week OVA-induced asthma model. 
 
2 week OVA-induced asthma model. Mice were anesthetized with an IP injection of 
100μL 0.9% NaCl (Merck) with 10mg/mL Ketamine and 1mg/mL Xylazine (Sigma-Aldrich®) and 
received an intranasal (IN) administration of 100μg OVA in 50μL.  
12 days later an IN administration of 25μg OVA in 50uL PBS was performed, a 
procedure that was repeated in the following two days.  
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Mice were killed on day 15 as previously mentioned (Figure 5).  
 
Figure 5 Time frame of the 2 week OVA-induced asthma model. 
 
HDM-induced asthma model. Mice were anesthetized with an IP injection of 100μL 
Ketamine/Xylazine. 50μg of HDM extract (GREER®) dissolved in 200μL PBS was administered 
IN on day 0, being this procedure repeated on days 10 and 11 with a lower amount of HDM 
(5μg in 50μL PBS). Mice were sacrificed 3 days after the last treatment by heart removal after 
washing and perfusion of the lungs (Figure 6). 
 
Figure 6 Time frame of the HDM-induced asthma model. 
1.3. Sample Harvesting 
Blood collection. Mice were anesthetized with an IP injection of 300μL 
Ketamine/Xylazine. Retro-orbital bleeding was performed using a capillary (BRAND®). 120μL of 
blood was collected into a 200μL capillary blood collection tube coated with 
ethylenediaminetetraacetic acid (EDTA) (KABE Labortechnik). The obtained sample was used 
for whole-blood analysis, and the serum utilized for the detection of IgE via an enzyme-linked 
immunosorbent assay (ELISA). 
 
BALF extraction.  BALF extraction is a technique commonly used to sample the 
epithelial lining fluid of the studied animals in order to study the influx of inflammatory cell 
populations after asthma induction.  
After confirming the animals’ lack of response to stimulation through paw pinching, 
the mouse was partially sterilized with 70% ethanol and a tracheostomy was performed. A 
small incision at the upper part of the trachea was used to expose the sternohyoid muscle, 
which was then cut longitudinally to reveal the trachea. This structure was punctured with a 
Vasofix® cannula (Braun Medical) and 200μL of ice-cold PBS was injected into the lungs using a 
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1mL syringe (BD™). This volume was aspirated and collected in a 2mL Eppendorf tube 
(Sarstedt) placed on ice. The lavage was repeated for a total volume of 2mL. This procedure 
yielded approximately 1.8mL of BALF.  
 
Lung digestion. Digestion of the lung was performed in order to study the 
inflammatory cell populations as well as the CD4+T cell subsets present in the tissue.  
To obtain single-lung-cell suspensions, lungs were first perfused with 20mL PBS 
through the right ventricle using a 22G needle (BD™). In the 5 week model, perfusion was 
firstly done with 20mL sodium nitroprusside dehydrate (Sigma-Aldrich®), a vasodilator used in 
order to better remove the blood from the tissue. 150mg of lung tissue was then cut into small 
pieces and digested for 30 minutes in 6-well plates (Corning® Costar®) at 6 g at 37ºC in PBS 
20% Collagenase A (10mg/mL, Roche) and 0.5% DNAse (Roche). Digestion was stopped with 
400μL of PBS/5% fetal bovine serum (FCS) (Biochrome)/4mM EDTA (Carl Roth)/0.5% DNAse. 
The supernatant was then filtered and the resulting suspension was used for flow cytometry. 
 
Lymph node extraction. The lymphatic system is actively involved in immune 
responses to foreign antigens. Therefore, the study of the characteristics of the lymphocytes 
residing in the lymph nodes provides information regarding the activation status of the T cells 
triggered by the lung DCs that migrate into these organs. 
The mouse skin was peeled from the forepaws and the brachial lymph nodes were 
collected using a tweezer. These organs were manually disrupted using frosted slide ends 
(Engelbrecht) into 2mL PBS/5%FCS and the ensuing cell suspension was then filtered into a 
2mL Eppendorf tube and used for flow cytometry. 
 
2. Inflammatory Cell Analysis 
2.1. Cytospin 
Cytospin is a method commonly used to concentrate the cells present in the sample on 
a restricted area of a slide, so that these can be stained and morphologically examined. It 
requires the use of a cytocentrifuge, that provides the centrifugal force required to gently fix 
the cells on the glass. 
150μL of BALF was inserted into reusable cytofunnels (Thermo Scientific) which were 
assembled over pre-labelled slides covered by a filter paper. These chambers were inserted 
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into a cytospin 3 cytocentrifuge (Shandon) and spun at 150 g for 8 minutes, with the 
acceleration of the rotor put to minimum. Slides were then carefully removed from the 
cytofunnels and allowed to dry. 
 
May-Grünwald-Giemsa Staining. May-Grünwald-Giemsa staining was performed on 
cytospins to allow identification of the various hematopoietic cells present in the BALF. Slides 
were placed in May-Grünwald Stain (Merck) for 3 minutes. This stain consists of a mixture of 
eosin, which is acidic, and methylene blue, which stains the acidic components of the cell. 
After this period, the samples were immersed in buffer solution pH 6.8 (Merck) for 5 minutes 
and then placed in diluted Giemsa solution (Sigma-Aldrich®) diluted 20 times in buffer solution 
for 20 minutes. Giemsa has specificity for the phosphate groups of DNA, staining the nucleus 
of cells in a purple color. The slides were then rinsed in buffer solution, allowed to dry and 
covered with a coverslip (Engelbrecht) using M Glass (Merck). 
2.2. Flow Cytometry 
2.2.1. Surface Staining 
Lung and BALF. All single-cell suspensions obtained from either BALF or digested lung 
tissue were stained for myeloid and lymphoid populations. Centrifugation of the samples was 
done at 145g for 7 minutes. The obtained pellet was re-suspended in 500μL PBS/5% FCS/4mM 
EDTA/0.5% DNAse. From this volume, 100μL of sample was loaded into a 96-well, V-bottom 
plate (Corning® Costar®). Samples were spun down at 402g for 2 minutes and incubated in 
50μL of antibody mix for 30 minutes on ice under dark. 
The myeloid staining mix included antibodies against CD45 (30-F11, eBioscience®), 
used to identify leukocytes while excluding erythrocytes and platelets; CD11b (M1/70, BD™), 
the C3 complement receptor, expressed highly in monocytes and macrophages, but also to a 
lower extent in granulocytes and some subsets of DCs; CD11c  (HL3, BD™), primarily expressed 
in DCs, but also in AMs; sialic acid-binding immunoglobulin-like lectin F (Siglec-F) (E50-2440, 
BD™), an inhibitory receptor on the surface of eosinophils, also expressed on the surface of 
AMs; Ly6G (1A8, eBioscience®), expressed at the surface of peripheral neutrophils; F4/80 
(BM8, eBioscience®), a macrophage surface marker; and MHC Class II (AF6-120.1, 
BioLegend®), present on the surface of antigen-presenting cells (APCs), such as macrophages 
and specially DCs, and whose expression is increased after antigen processing by these cells. 
4',6'diamidino-2-phenyldole (DAPI) (Life Technologies™) was used in order to assess the cell 
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viability, as this fluorescent binds to DNA and fluoresces as the membrane integrity of dead 
cells is compromised. 
The lymphoid staining mix was composed of antibodies against CD45; CD45R (B220) 
(RA-6B2, eBioscience®), an epitope mainly expressed by the B cell lineage; CD3 (145-2C11, 
eBioscience®), a complex that is required for assembly, trafficking and expression of the T-cell 
receptor (TCR), being expressed at the surface of T cells; CD4 (GK1.5, eBioscience®), a co-
receptor of the TCR expressed by Th cells; and CD8 (H35-17.2, eBioscience®), a co-receptor of 
the TCR found at the surface of T cytotoxic cells. DAPI was used as an indicator of cell viability. 
After staining, samples were spun at 402g for 2 min and re-suspended with 300μL 
PBS/5%FCS/4mM EDTA/0.5% DNAse.  
 
Lymph nodes. Lymph node single-cell suspensions were stained for lymphocytic 
populations. Briefly, samples were spun for 7 minutes at 402g and the obtained pellet was re-
suspended in 1mL PBS/5% FCS/4mM EDTA/0.5% DNAse. From this volume, 150μL of sample 
was loaded into a 96-well plate, V-bottom and a surface staining procedure already described 
was performed. 
The antibody mix consisted of antibodies against CD3 (eBio500A2, eBioscience®), CD4 
(GK1.5, eBioscience®), and CD8 (53-6.7, eBioscience®) in order to identify the T cell 
populations. Anti-CD19 antibody (MB19-1, eBioscience®) was used to identify B cells, as this 
molecule associates with their B cell receptor. Anti-CD69 antibody (H1.2F3, eBioscience®) was 
used in order to identify recently activated cells; CD62L (L-selectin) (MEL-14, BioLegend®) was 
used as a marker for naïve lymphocytes. DAPI was used as an indicator of cell viability. 
 
2.2.2. Intracellular staining 
T cell subsets. Th cells can differentiate into several subtypes, which have distinct 
transcription factors regulating their activity. The study of the Th cell subpopulations in asthma 
allows the analysis of the PHD2-mediated T helper cell polarization.  
100μL of lung cell suspension was used for this staining in a 96-well plate, V-bottom. 
After centrifugation at 402g for 2 minutes, samples were stained with antibodies against the 
surface markers CD45 (30-F11, eBioscience®), CD3 (145-2C11, eBioscience®) and CD4 (GK1.5, 
eBioscience®). Staining lasted 30 minutes and was done at 4ºC in the dark. 
After the surface staining, cells were washed with PBS. The intracellular staining was 
done using the Foxp3 / Transcription Factor Staining Buffer Set (eBioscience®). 200μL of FoxP3 
Fixation/Permeabilization solution diluted with diluent (1:4 vol/vol) was added to each well 
and samples were left incubating in the dark overnight.  
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200μL of permeabilization buffer diluted with distilled water (1:10) was added to each 
well after centrifugation at 226g for 2 minutes. 3μL of each intracellular antibody was added to 
each well in 100μL permeabilization buffer. FoxP3 (FJK-16s, eBioscience®) was used as a 
marker for Treg cells, whereas GATA3 (TWAJ, eBioscience®) was used in order to identify the 
Th2 subset. The staining was done for 30 minutes under dark conditions at 4ºC. Samples were 
washed twice and then re-suspended in 300μL of PBS for flow cytometric analysis. 
 
2.2.3. Compensation controls 
Compensation controls for every staining were done using OneComp eBeads 
(eBioscience®) or fixed single-bone marrow cell suspensions in case of the intracellular 
staining. For the latter, a femur was removed from one mouse and flushed with 2mL of 
PBS/5%FCS using a 23G needle (BD™). The obtained suspension was then filtered and 
centrifuged for 2 min at 402g. Cells were fixed using the same protocol as mentioned for the 
intracellular staining. 
 
Flow cytometric analysis was performed on LSR II Flow Cytometer (BD™) and data was 
analyzed using FlowJo Version 10 software (TreeStar). All used antibodies and respective 
target cells are summarized in Table 1. Gating strategies of the myeloid, lymphoid and lymph 
node staining are depicted in  Figures 38, 39 and 40 of the Appendix, respectively. 
 
Table 1 Antibodies used in this work and their respective target population. 
Antibody Target population 
CD45 – FITC (clone 30-F11) Leukocytes 
CD11b – AmCyan (clone M1/70) Monocytes and Macrophages 
CD11c - APC-cy7 (clone HL3) DCs and AMs 
Siglec-F – PE (clone E50-2440) Eosinophils and AMs 
Ly6G- APC (clone 1A8) Neutrophils 
F4/80 - PE-cy5 (clone BM8) Macrophages 
MHC II – PE-cy7 (clone AF6-120.1) APCs 
B220 – PE-cy7 (clone RA-6B2) B cells 
CD3-APC (clone 145-2C11) 
CD3 – Alexa Fluor 700 (eBio500A2) 
T cells 
CD4 – PE (clone GK1.5) Th cells
 
CD8 – PE-cy5 (clone H35-17.2) 
CD8 – PE-cy7 (53-6.7) 
Cytotoxic T cells 
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CD19 – FITC (clone MB19-1) B cells 
CD69 – APC (clone H1.2F3) Activated lymphocytes 
CD62L – PerCP (clone MEL-14) Naïve lymphocytes 
FoxP3 -  Alexa Fluor® 488 (clone FJK-16s) Treg cells 
GATA3 - eFluor® 660 (clone TWAJ) Th2 cells 
DAPI Dead cells 
 
2.2.4. Cell Quantification 
Absolute cell numbers in BALF, lung and lymph nodes. Total cell counts were 
obtained through MACS Quant (Myltenyi) measuring. 10μL of sample was loaded into a 96-
well plate, flat bottom (Corning® Costar®) in 90μL of PBS/5%FCS/0.1% DAPI. 1μL of anti-CD45 
was added to each well. The samples were incubated for 30 minutes under dark conditions at 
4ºC. This method allows the enumeration of the absolute number of live cells that express the 
CD45 surface marker, providing for total numbers of each cell population analyzed in flow 
cytometry. The acquired results were examined using FlowJo Version 10 software (TreeStar). 
 
Whole blood analysis. Blood parameters were determined using an automated blood 
cell counter XT-4000 (Sysmex). Platelet counts, hemoglobin and hematocrit concentration and 
white and red blood cell numbers in circulation were measured, as well as lymphocyte, 
monocyte, eosinophil and neutrophil numbers. 40μL of blood was diluted 1:5 in 0.9% saline 
solution for measurement. The remaining blood was centrifuged at 502g for 2 min and the 
plasma was collected and stored at -80ºC until an IgE ELISA was performed. 
 
 
3. Biochemical Analysis 
3.1. Lung Tissue Analysis 
Lung tissue was obtained for cytokine analysis by ELISA and electrochemiluminescence 
(ECL). The tissue was homogenated in 500μL of cOmplete Protease Inhibitor (Roche) in 
PBS/0.05% Tween-20 (VWR®), centrifuged at full speed for 10 minutes and the supernatant 
was collected.  
 
24 
 
Bradford assay. A Bradford assay was performed for total protein concentration 
measurement. This colorimetric protein assay relies on the absorbance shift of the Coomassie 
Blue dye when bound to proteins in the sample.  
25uL of each sample was used to prepare successive dilutions (1:5) of the sample in 
PBS/0.05% Tween-20/% cOmplete. A bovine serum albumin (BSA) standard (2mg/mL) (Thermo 
Scientific) was diluted in the same diluent, with successive two-time dilutions to a final 
concentration of 125mg/mL. 250μL of Bradford Reagent (Bio-Rad) was loaded into a 96-well 
plate, flat bottom. From either sample, standard or diluent, 5μL was loaded to each well. 
Absorbance was measured at 595nm using a Synergy™HT Reader (BioTek). After analysis of 
total protein content, 30 to 50μg of protein was used for cytokine measurement.  
 
IL-5 and IL-13 ELISA. An ELISA is an analytic biochemical assay that involves the 
detection of an antigen of interest through binding with a set of specific antibodies followed 
by the enzymatic cleavage of a substrate. Sandwich ELISAs ensure specificity of the obtained 
signal by the use of an antibody against the antigen that binds it to the surface of the 
polystyrene plate (capture antibody) and a second antibody against this substance that is 
biotinilated (detection antibody), assuring binding with the enzyme used for the color reaction 
which in turn is bound to Avidin, a tetrameric biotin-binding protein.  
Mini ELISA Development Kits (Peprotech®) were used for the IL-5 and IL-13 ELISAs. 
High-affinity binding 96-well flat bottomed plates (Greiner Bio-One) were coated overnight at 
room temperature with 100μL capture antibody in PBS. After washing of the plate 4 times 
with 0.05% Tween-20 in PBS, blocking of the plate was done for one hour with 300μL 
PBS/1%BSA (Sigma-Aldrich®). After washing, the respective volume of each sample and 
standard was added to the plate and successive dilutions (1:3) were performed for every 
sample. Dilutions were made in PBS/0.05% Tween-20/0.1%BSA. Incubation with the samples 
lasted 2 hours, followed by 4 washing steps. 100μL of detection antibody was added and the 
plate was left incubating for another 2 hours. 100μL of Avidin-horseradish peroxidase (HRP) 
conjugate (1:2000) was used and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) 
Liquid Substrate Solution (Sigma-Aldrich®) was then added after washing for color 
development. Optical density (O.D.) was measured after 30 minutes at 405nm with a 
wavelength correction at 650nm with a Synergy™HT Reader (BioTek). 
 
ECL assay. An ECL assay is a highly sensitive sandwich immunoassay used to measure 
the levels of particular protein targets in a single sample. This technique is based on the 
principle that under an appropriate chemical environment, the application of a voltage to the 
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solution leads to the excitation of the electrochemiluminescent labels used, which emit light 
upon relaxation. Multiple labels can be coupled to the proteins in the sample, from which the 
instrument measures the intensity of emitted light in order to quantify the particular proteins 
of interest in the sample. 
A Proinflammatory Panel 1 (mouse) Kit (MSD®) was used to measure the 
concentration of IL-10, an anti-inflammatory cytokine mainly produced by monocytes and Treg 
cells; IL-1β, a pro-inflammatory cytokine produced by activated macrophages; IL-4, mainly 
produced by Th2 cells; IL-6, a pro-inflammatory cytokine mainly produced by Th1 cells and 
macrophages; and TNF-α, also pro-inflammatory and produced mainly by macrophages.  
Lung tissue homogenate was diluted in Diluent 41, provided in the kit, to a final 
concentration of 0.6mg/mL. The standard was successively diluted (1:2) in Diluent 41, 
according to the manufacturer’s instructions. From either sample or standard solutions, 50μL 
was added to the plate, which was left incubating at room temperature with shaking for 2 
hours. The plate was washed 3 times with 200μL PBS/0.05% Tween-20 and 25μL of antibody 
solution including antibodies for all of the above mentioned cytokines was added to each well. 
Incubation with the antibody mix lasted 2 hours under the same conditions as for the samples, 
the wells were washed and 150μL of Read Buffer T in deionized water (1:2) were added to 
each well just prior to measuring. Measurement of the plate was done on a QuickPlex SQ 120 
(MSD®) and analysis of the results was carried out using the MSD Discoveery Workbench® 
analysis software (MSD®). 
3.2. Plasma Analysis 
 IgE ELISA. A Mouse IgE Ready-SET-Go!® (eBioscience®) kit was used in order to 
measure IgE levels in the plasma obtained from the retro-orbital bleeding. The high-affinity 96-
well plate was coated with capture antibody overnight at 4ºC. Washing was done twice with 
0.05% Tween-20/PBS and the plate was blocked with 250μL of blocking buffer prepared 
according to the manufacturer’s instructions for 2 hours. Next, the plate was washed as 
described previously and samples/ standards were diluted in the Assay Buffer A provided by 
the kit and added to the wells. Incubation lasted 2 hours, after which the plate was washed 
and incubated with 100μL of detection antibody for another hour at room temperature on a 
microplate shaker PMR-30 (Grant) at 30 oscillations per minute. 100μL of streptavidin-HRP 
were used as the reporter and incubation with this complex was done for 30 minutes. The 
plate was washed another 4 times and 100μL of Substrate Solution provided in the kit was 
added to each well, and incubated for 15 minutes. The reaction was stopped by adding 100μL 
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2M sulfuric acid (H2SO4). The plate was read at 450nm with a wavelength correction at 570nm 
using a Synergy™HT Reader (BioTek). 
 
 
4. Histological Analysis 
4.1. Tissue Preparation 
Histological analysis of the lung tissue allows for a quantification of the degree of 
disease in each individual animal. This technique is used to measure tissue alterations and 
remodeling that are the result of the asthmatic triggering. 
Lung tissue was collected from each mouse and fixed overnight in 4% 
Paraformaldehyde (PFA) (Carl Roth) at 4ºC. Samples were then processed in order to remove 
the water from the tissue and replace it with paraffin. Briefly, samples were transferred 
through baths of progressively higher ethanol concentrations, being then immersed in xylene 
and, subsequently, paraffin wax. Embedding was done using a TES Valida (MEDITE), where 
samples were placed into molds and covered with paraffin externally. 2μm cross sections of 
the blocks were cut using a RM 2235 microtome (Leica) and mounted on glass microscope 
slides. 
As the staining solutions used are aqueous, sections were rehydrated prior to staining. 
Samples were passed through Roticlear (Carl Roth), a xylene alternative used as a clearing 
agent, for 15 minutes, followed by 5 minute incubation in decreasing strengths of ethanol 
(100/90/80/70%). Finally sections were incubated in distilled water.  
Upon completion of all performed stainings (see below), all slides were washed, 
dehydrated and incubated in Roticlear for 15 minutes. Mounting was done with VectaMount 
(Vector Laboratories) and a coverslip was placed on top to protect the samples. 
4.2. Histological Staining 
Haemotoxylin and Eosin (H&E) Staining. H&E is one of the most commonly used 
histological staining, involving the use of an acidic (Eosin) and a basic dye (Haematoxylin). 
Eosin stains basic structures, such as the cytoplasm of cells and protein structures, in pink; 
whereas the latter stains acidic structures, such as the nucleus of cells, in a purplish blue. This 
staining was used in order to assess cell infiltration in the lung tissue. 
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After rehydration, the slides were immersed in Mayers Haematoxylin (SAV Liquid 
Production) for 5 minutes. Warm water was used to rinse the samples, which were then 
submerged in Eosin (Klinik Apotheke) for 3 minutes. 
 
Periodic Acid Schiff (PAS) staining. PAS staining is a method used to detect 
polysaccharides, glycoproteins and mucins in tissues. Periodic acid oxidizes these sugars, 
forming aldehydes that react with the Schiff reagent, giving a dark pink color. Haematoxylin is 
then used as a counterstain and the final outcome is used to assess mucus production by the 
Goblet cells in the bronchi of the tissue. 
Slides were incubated in 2% Periodic Acid (VWR) for 15 minutes. After a short 
immersion in distilled water, all slides were transferred to a Schiff Reagent (SAV Liquid 
Production) container, where they were left submerged for 20 minutes. Washing was done 
with water and samples were counterstained for 5 minutes in Mayers Haematoxylin. 
 
Masson Trichrome (MT) staining. This particular staining was performed in the 
Institute of Pathology of the University Hospital Carl Gustav Carus. This staining allows the 
distinction between cells and the surrounding connective tissue, involving the usage of three 
solutions that stain the nuclei and the cytoplasm of the cells and the collagen fibers. The final 
result leads to the cell staining in red, while the collagen fibers are stained in blue, allowing the 
quantification of the fibrous area of the tissue. 
4.3. Microscopy 
Light microscopy was done with an Axioplan-2 imaging microscope (Carl Zeiss). The 
cameras and acquisition software were Axiocam MRc5 and Axiovision. Image processing and 
analysis was done using ImageJ version 1.47V. 
 
 
5. Statistical Analysis 
Data and graphs represent mean ± SEM of representative experiments. Statistical 
significance was calculated as two-tailed by Students t-test (GraphPad Prism v6®), with p<0.05 
considered statistically significant.  
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Results and Discussion 
1. Induction of the Asthmatic Response 
1.1. Inflammatory cell Infiltration Analysis 
In order to induce an asthmatic phenotype in the studied mice, a 5 week model of 
OVA-induced pulmonary inflammation was first applied. Morphological examination of the 
infiltrating inflammatory cells in the BALF was performed using cytospin and May-Grünwald-
Giemsa staining (Figure 7). Nuclei are stained with a dark purple color due to the staining with 
the basic dye, while the cytoplasm stains light blue or pink due to the low concentration of 
nucleic acids. 
Untreated WT mice showed little cell amounts in the BALF, being the major population 
in this sample cells with a small nucleus to cytoplasm ratio, which correspond to the AM 
population, present in the airway under steady state conditions. AMs represent the majority 
of cells in the airway in healthy mice35 and these macrophages have extensive cytoplasmic 
areas (Figure 7A). As the junctions between epithelial cells in the bronchi of asthmatic mice 
are loosened, washing of the airway in triggered mice allows the extraction of inflammatory 
cells that migrate through these structures into the alveolar space to defend the organism 
against the inhaled antigen. Therefore, in asthmatic mice a high cell infiltration was observed 
in the BALF, composed mainly of various inflammatory cell types with very distinct 
morphologies (Figure 7B).  
      
Figure 7 May-Grünwald-Giemsa staining of the cytospin obtained from inflammatory cells in the BALF 
of untreated (A) or OVA-treated mice (B). Cells nuclei are stained with a dark purple color, being the 
cytoplasm light blue or pink due to the low concentration of nucleic acids. 
 
A
  A 
B
  A 
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Several inflammatory cells are involved in the pathology of asthma. Activation of the T 
cells in the lymph nodes by the DCs leads to their migration into the lung tissue and 
consequent recruitment and activation of downstream inflammatory cells such as eosinophils 
and neutrophils6.  
Analyzing samples from asthmatic mice under higher magnification, gave the 
possibility to characterize the aforementioned populations and therefore identify the 
infiltrating cells in the BALF under allergic airway conditions (Figure 8).  
 
 
Figure 8 May-Grünwald-Giemsa staining of the cytospin obtained from inflammatory cells in the BALF 
of OVA-treated mice. Infiltration of several distinct cell populations was observed, mainly AMs (1), 
lymphocytes (2), neutrophils (3) and eosinophils (4). 
 
AMs and lymphocytes both display a single one-lobed nucleus, but the first possess big 
cytoplasmic area comparing to their nuclear space (1), while the second show a large nucleus 
to plasma ratio (2). Eosinophils and neutrophils, however, are polymorphonuclear cells, 
showing lobed nucleus, which makes them easily distinguishable from the other cell types. 
While the neutrophil cytoplasm is stained in pale blue (3), eosinophil granules, which are 
alkaline, are stained in orange (4) due to the binding of eosin to these structures (Figure 8). 
Analyzing the cell populations in the BALF from triggered mice, the eosinophil population 
arose as the major cell type in the samples. This cell population produces cytokines and other 
mediators that contribute to the pathology of asthma25, being the migration of these cells into 
the lung during asthma correlated with symptom scores38 
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1.2. Mucus Production in the Lung 
During asthma, there is an induction of the remodeling of the lung tissue. As a 
response to the damage of the epithelium, epithelial cells proliferate and differentiate into 
Goblet cells, which are mucus-producing cells6. In healthy epithelium (Figure 9A), mucus 
production is negligible. However, after asthma induction, it is possible to observe the 
presence of Goblet cells in the epithelium that stain for PAS, turning dark pink (Figure 9B). 
Mucus production by Goblet cells has a protective purpose, as this substance traps antigens in 
the airway space, not allowing their invasion onto the tissue. However, the production of 
mucus by the epithelial cells in the lung during asthma is excessive and can contribute to the 
airway obstruction observed in asthmatic patients4. 
      
Figure 9 PAS staining of sections from either untreated WT (A) or WT-triggered (B) lung. Mucins are 
stained in dark pink and associate with the presence of Goblet cells in the bronchus.  
 
The asthmatic triggering was performed on WT mice, as well as on cKO mice for PHD2 
in either the T cells, CD4:cre-PHD2f/f, or the myeloid cells, LysM:cre-PHD2f/f. To assess if the 
responsiveness to the OVA-treatment was affected by the deletion of PHD2 in either the T cell 
or myeloid cell compartment, the mucus production in the bronchi of asthmatic mice was 
analyzed. As histology gives a clear indication of the severity of the phenotype, quantification 
of the Goblet cell coverage in bronchi of lungs from each genotype was performed (Figure 10). 
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Figure 10 Goblet cell quantification in lung sections from untreated WT (n=8), WT-triggered (n=18), 
CD4:cre-PHD2
f/f
-triggered (n=15) and LysM:cre-PHD2
f/f
-triggered mice (n=6). The percentage of 
bronchi expressing Goblet cells (A) and the overall Goblet cell coverage in the lung (B) were measured. 
Data are presented as mean ± SEM.  n.e. – not expressed; n.s. – not significant; ****p<0.0001. 
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The epithelial remodeling was observed for all genotypes, with approximately 44% 
(±14%) of the bronchi in the tissue expressing Goblet cells (Figure 10A) and with an increase of 
Goblet cell coverage from zero up until approximately 15% (±7%) in asthmatic WT mice (Figure 
10B). A significant increase in the percentage of bronchi expressing the Goblet cells and total 
Goblet cell coverage in the lung tissue was observed for the CD4:cre-PHD2f/f mice in 
comparison with the WT-triggered mice. This indicates a more severe asthma phenotype. No 
significant differences were observed between the WT-treated and the LysM:cre-PHD2f/f-
treated mice. 
Given the higher susceptibility of the CD4:cre-PHD2f/f to asthma, this genotype was 
further analyzed for other tissue remodeling parameters, as well as inflammatory cell numbers 
in BALF and lung tissue and cytokine concentration.  
 
 
2. The Role of PHD2 in T cells during Asthma 
2.1. 5 week OVA-induced Asthma Model 
2.1.1. Tissue remodeling evaluation 
Epithelial cell proliferation subsequent to cytokine stimulation upon asthma is one of 
the major causes for the bronchoconstriction observed in asthmatic patients. The proliferating 
cells can give rise to Goblet cells, increasing the mucus production in the bronchi and 
aggravating the disease outcome3,6. To analyze the proliferation of epithelial cells in both OVA-
treated groups, the ratio between the luminal area and the total bronchi area was quantified 
(Figure 11).  
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Figure 11 Bronchial luminal area quantification of CD4:cre-PHD2
f/f
 mice in the 5 week OVA-induced 
asthma model. Lung sections from untreated WT (n=5), WT-triggered (n=16) and CD4:cre-PHD2
f/f
-
triggered (n=13) were analyzed using ImageJ. Bronchial luminal area is expressed as the ratio between 
the lumen area and the total area of the bronchus. Data are presented as mean ± SEM. n.s. – not 
significant. 
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No differences in bronchial thickness were observed between triggered and untreated 
mice. As Goblet cell coverage was observed for all OVA-treated mice, with a significant 
increase in the CD4:cre-PHD2f/f mice comparing to the WT, this could indicate that these cells 
are being originated from metaplasia and not hyperplasia of the cells of the epithelium. 
 
During asthma, there is an increase in collagen deposition surrounding the bronchi, as 
the result of the continued stimulation of fibroblasts by the pro-fibrotic mediators produced 
by the damaged epithelium6. Therefore, this parameter was investigated in the asthmatic WT 
and CD4:cre-PHD2f/f mice, as the latter showed a stronger phenotype in the Goblet cell 
presence in the bronchi (Figure 12). 
     
Figure 12 Masson Trichrome (MT) staining of sections from either untreated WT (A), WT-triggered (B) 
or CD4:cre-PHD2
f/f
 lung (C). Collagen fibers are stained in a blue color, allowing the quantification of the 
fibrous area of the tissue. 
 
Comparing the bronchi from untreated (Figure 12A) with OVA-treated mice (Figure 
12B), it is possible to observe a higher collagen deposition surrounding this structure upon 
asthmatic triggering. This feature is maintained for the CD4:cre-PHD2f/f mice triggered with 
OVA (Figure 12C) and represents one of the major hallmarks of the disease. Collagen fibers are 
stained in blue, being easily distinguishable from the cells, stained in red. The proportion of 
the collagen area in proportion to the bronchial area was quantified for each sample using 
ImageJ (Figure 13). 
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Figure 13 Quantification of the collagen deposition surrounding the bronchi in CD4:cre-PHD2
f/f 
mice in 
the 5 week OVA-induced asthma model. Lung sections from untreated WT (n=5), WT-triggered (n=16) 
and CD4:cre-PHD2
f/f
-triggered (n=13) were analyzed using ImageJ. Collagen encircling the bronchi is 
expressed as the ratio between the collagen-covered area and the area of the bronchial wall. Data are 
presented as mean ± SEM. n.s. – not significant. 
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An increase in collagen deposition surrounding the bronchi occurs after treatment 
with OVA, confirming the asthmatic phenotype; however, no differences were observed 
between genotypes.  
The fibrotic changes in the lung tissue are a downstream effect of the alterations 
observed in the lung epithelium, as well as TGF-β production by the inflammatory cells6. Thus, 
the comparable deposition of collagen between genotypes can be the result of an equal pro-
fibrotic mediator production by the epithelial cells as well as a plateaued production of TGF-β 
by the immune cells invading the lung, which should be confirmed via ELISA. 
 
Vascular remodeling in the lung occurs under hypoxic conditions and leads to a 
heightening in pulmonary resistance. All cell layers of the vessels increase their proliferation 
rates, resulting in a reduction in the luminal area of the vessel44 (Figure 14). 
 
     
Figure 14 Artery remodeling in the lung of untreated WT (A), WT-triggered (B) and CD4:cre-PHD2
f/f
 
mice (C). The SMC in the media layer are stained in pink, being the endothelial cells in the intima 
marked in purple. 
 
Under steady state conditions (Figure 14A) arteries present a high lumen/vessel ratio, 
being the arterial wall thin and very well delimited. However, in both WT (Figure 14B) and 
CD4:cre-PHD2f/f (Figure 14C) mice it is possible to observe a thickening of the SMC layer, as 
well as proliferation of the endothelial cells to the interior of the arterial lumen, consistent 
with vascular remodeling. The ratio between luminal area and vascular area was quantified for 
both asthmatic groups using ImageJ (Figure 15). 
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Figure 15 Quantification of the vascular remodeling in the lung in CD4:cre-PHD2
f/f
 in the 5 week OVA-
induced asthma model. Lung sections from untreated WT (n=5), WT-triggered (n=18) and CD4:cre-
PHD2
f/f
-triggered (n=16) were analyzed using ImageJ. Vascular luminal area is expressed as the ratio 
between the lumen area of the vessel and the total area of the vessel. Small vessels depict vessels with 
a total area smaller than 10mm
2
, being the large vessels of sizes above the aforementioned. Data are 
presented as mean ± SEM. n.s. – not significant; *p<0.05. 
 
In both WT and CD4:cre-PHD2f/f mice, there was a significant reduction in vascular 
lumen (Figure 15A), for both vessels with an area smaller than 10mm2 (Figure 15B) and large 
vessels (with an area higher than 10mm2) (Figure 15C). There is a trend for a lower luminal 
fraction in the vessels of the CD4:cre-PHD2f/f mice comparing with the WT, which is only 
significant for larger structures (Figure 15C). The vascular remodeling in the asthmatic mice 
from both groups causes an increase in pulmonary resistance and represents a hindrance in 
lung perfusion, leading to the need of a vasodilator and limiting the inflammatory cell 
quantification in the tissue due to possible contamination with blood. 
 
 
2.1.2. Inflammatory cell infiltration analysis 
As the asthmatic phenotype seemed to be more aggravated in the CD4:cre-PHD2f/f 
mice, inflammatory cell infiltration was assessed for both BALF and lung tissue using flow 
cytometry (Figure 16). This technique allowed obtaining relative as well as absolute cell 
numbers of each leukocyte population.  
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Figure 16 Inflammatory cell infiltration in the BALF of CD4: cre PHD2
f/f
 mice in the 5 week OVA-
induced asthma model. The percentage (A) or total counts (B) of each leukocyte cell population were 
assessed by flow cytometry in the BALF of WT-triggered (n=4) and CD4:cre-PHD2
f/f
-triggered mice (n=4). 
Data are presented as mean ± SEM. n.s. – not significant. 
 
Although the mucus production is more exacerbated in the CD4:cre-PHD2f/f mice, with 
a tendency for higher vascular remodeling when comparing with WT littermates, no 
differences in inflammatory cell infiltration exist between these groups in either percentage 
(Figure 16A) or absolute number of cells (Figure 16B). The lack of differences between 
genotypes might indicate that at the analyzed time point the infiltration of cells into the BALF 
is not the major factor driving the pulmonary tissue changes observed.  
Migration of the inflammatory cells into the alveolar space during asthma occurs due 
to the loosening of the epithelial junctions in the bronchi after damage and shedding of the 
ciliated cells in the epithelium6. Thus, a lower cell number in the lung tissue could be an 
indication of looser junctions in the epithelium and, therefore, more tissue damage. To 
investigate this hypothesis, cell infiltration in digested lung tissue was analyzed (Figure 17). 
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Figure 17 Inflammatory cell infiltration in the lung tissue in CD4:cre-PHD2
f/f
 in the 5 week OVA-
induced asthma model. The percentage (A) or total counts (B) of each leukocyte cell population were 
assessed by flow cytometry in the digested lung tissue of WT-triggered (n=4) and CD4:cre-PHD2
f/f
-
triggered mice (n=4). Data are presented as mean ± SEM. n.s. – not significant. 
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No differences were observed between genotypes in cell percentages in the lung 
tissue (Figure 17A). There seemed to be a trend for a lower leukocyte number in the lung 
tissue in the CD4:cre-PHD2f/f mice, however not significant (Figure 17B). This tendency 
resulted from a high variability between individuals of the same group. Although the same 
quantity of lung tissue was taken for digestion in order to standardize the cell numbers in the 
tissue and allow a comparison between groups, this technique has limitations, such as the 
aforementioned blood contamination, human factors associated with the cutting of the tissue 
and loss of cells during the filtration process which might explain the obtained results. 
However, considering the lack of differences between the groups for either leukocyte 
amounts in the BALF or in the lung tissue, both genotypes might display similar epithelial 
barrier damage and at the analyzed time point cell infiltration might not be contributing to the 
observed phenotype. Therefore, the increased mucus production observed in the CD4:cre-
PHD2f/f mice could occur due to higher cell activation and not increased cell numbers in the 
lung. 
 
 
2.1.3. Lymph node lymphocyte analysis 
As CD4:cre-PHD2f/f mice have a conditional deletion of PHD2 in the T cell compartment 
and T cell activation by the DCs plays a major role in asthma, the brachial lymph nodes from 
asthmatic mice were collected and analyzed for each T cell population in regards to their 
activation state (Figure 18). 
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Figure 18 Lymphocyte populations in the lymph node in CD4:cre-PHD2
f/f
 in the 5 week OVA-induced 
asthma model. The percentage (A) or total counts (B) of each leukocyte cell population were assessed 
by flow cytometry in the brachial lymph nodes of WT-triggered (n=4) and CD4:cre-PHD2
f/f
-triggered 
mice (n=4). Data are presented as mean ± SEM. n.s. – not significant. 
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Analyzing both genotypes with regard to their cell percentages gave no differences 
between WT and CD4:cre-PHD2f/f mice (Figure 18A). Lymphocyte cell numbers were also 
comparable between genotypes, although a trend for higher cellularity in the CD4:cre-PHD2f/f 
mice seemed to exist due to the high variability between individuals in the same group (Figure 
18B). Once again the processing of the tissue might have led to a high variable yield that could 
be interfering with the obtained results.  
As the same number of recently activated (CD69+) CD4+ T cells existed for both 
genotypes, it is possible to conclude that the observed phenotype in the CD4:cre-PHD2f/f group 
is probably independent of the maturation and activation of these cells by the DCs in the 
lymph nodes. As the T cell numbers in this tissue were also comparable to what was observed 
in the WT mice, proliferation of the T cells in the lymph nodes is also not enhanced in the cKO. 
 
 
2.1.4. Whole blood analysis 
No differences in leukocyte numbers were observed in BALF, lung or lymph nodes of 
both genotypes. As this can indicate that at the analyzed time point cell activation and 
infiltration in the tissue is not occurring at the same extent as it would in the beginning of the 
asthmatic response, the blood parameters and inflammatory cells in migration were 
investigated for both genotypes. Blood from asthmatic mice from both groups was analyzed 
for inflammatory cell levels in order to assess if more cells are in circulation upon asthma 
triggering. Hematological parameters such as platelets, hemoglobin, hematocrit and white and 
red blood cells in circulation were the same for both groups (Figure 19), showing that deletion 
of PHD2 in the T lymphocytes has no effect on these blood elements during asthma induction. 
Blood analysis was performed using the Sysmex hematological analyzer, which allowed the 
measurement of each hematological parameter and cell population levels in the blood. 
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Figure 19 Whole blood quantification of platelets (PLT), hemoglobin (HGB), hematocrit (HCT), white 
blood cells (WBC) and red blood cells (RBC) in both WT-triggered (n=9) and CD4:cre-PHD2
f/f
-triggered 
mice (n=10). Measurement of these parameters was performed using a Sysmex hematological analyzer 
(XT-4000). Data are presented as mean ± SEM. n.s. – not significant. 
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Comparing the WT asthmatic mice with the CD4:cre-PHD2f/f, no discrepancy was 
observed for the amount of circulating lymphocytes, monocytes, eosinophils or neutrophils 
(Figure 20). 
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Figure 20 Leukocyte population numbers in circulation in CD4:cre-PHD2
f/f
 in the 5 week OVA-induced 
asthma model. Leukocyte subpopulations were quantified in both WT-triggered (n=9) and CD4:cre-
PHD2
f/f
-triggered mice (n=10) using a Sysmex hematological analyzer (XT-4000). Data are presented as 
mean ± SEM. n.s. – not significant. 
 
The comparable numbers of the aforementioned leukocytes in circulation indicates 
that the recruitment of these cells to the tissue is neither impaired nor enhanced in the 
CD4:cre-PHD2f/f mice, which is in agreement with the cell numbers in both lung tissue and 
BALF. Although no differences exist between cell numbers in either the BALF or lung tissue in 
WT or CD4:cre-PHD2f/f mice and the migration of these cells to the tissue is not altered, T cell 
differentiation might be affected in the cKO mice due to the lack of PHD2 in the T cell 
compartment. 
 
 
2.1.5. Th cell differentiation analysis 
In order to study the Th cell subpopulations in the lung tissue of asthmatic mice, an 
intracellular staining was performed for Th2 cells, which are the major cells involved in the 
eosinophil chemotaxis and activation as well as the induction of the tissue remodeling. Treg 
cells, on the other hand, have a regulatory effect and are involved in controlling and 
diminishing the activation of the effector cells26. For both WT and CD4:cre-PHD2f/f mice it was 
possible to observe a cell population positive for both GATA3, the master transcription factor 
for Th2 cells, and FoxP3, the transcription factor regulating Treg cells (Figure 21). These cells 
might represent a transient population differentiating from Th2 to Treg, which might indicate 
the beginning of the resolution of inflammation. 
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Figure 21 Th cell differentiation in the lung tissue in the 5 week OVA-induced model. Flow cytometry 
was used to analyze the Th2 (GATA3
+
) and Treg (FoxP3
+
) populations in the lung tissue. A population 
expressing both transcription factors is observed for all samples. 
 
Although GATA3 and FoxP3 were thought to be mutually exclusive transcription 
factors, Th2 cells have been shown to be able to switch to a Treg phenotype51. The double 
positive (DP) population has been observed in mouse models of allergic asthma by other 
groups to express both master transcription factors of Treg and Th2 cells, with lower 
intracellular expression of IL-4, IL-5 and IL-13 comparing to the Th2 cells51,52. These Th2 
memory-derived Tregs could also actively suppress proliferation and production of cytokines 
by the Th2 cells, as well as tissue eosinophilia and IgE levels, albeit in a slightly reduced 
potency when compared to Tregs51. Little is known about the mechanisms involved in the 
aforementioned transition, but it might be induced as a defense response that propitiates the 
beginning of an anti-inflammatory response in the tissue. 
Interestingly, the Th2 fraction was significantly reduced in the CD4:cre-PHD2f/f lungs, 
whereas Treg cells were induced (Figure 22). 
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Figure 22 Th cell subpopulations in the lung tissue in CD4:cre-PHD2
f/f
 in the 5 week OVA-induced 
asthma model. Quantification of the percentage of Th2, Treg and DP cells was done for both WT-
triggered (n=3) and CD4:cre-PHD2
f/f
-triggered mice (n=5). Data are presented as mean ± SEM. n.s. – not 
significant; *p<0.05. 
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As CD4:cre-PHD2f/f mice show a more severe mucus production, associated with a 
more intense asthma phenotype, a higher amount of differentiated Th2 cells would be 
expected, as this Th cell subpopulation is the major intervenient in asthma. However, the 
existence of a transition population between the Th2 and Treg subsets might indicate that at 
this stage of disease there is a feedback mechanism that prompts a conversion of the Th2 cells 
into a regulatory phenotype and therefore no further stimulation of the asthmatic response 
occurs. The observed Treg population is composed of both nTregs and iTregs generated in the 
lung tissue. Therefore, the trend for higher Treg percentages in the CD4:cre-PHD2f/f mice 
might come from increase of iTregs. The cells that originate from this activation suppress the 
pulmonary DC activation in a more effective manner than the DP population through the 
production of anti-inflammatory cytokines such as IL-10 and TGF-β29. 
 
As iTreg cells are generated under the control of DCs with low expression of MHC II4, 
quantification of its expression was performed. Mean fluorescence intensity (MFI) due to MHC 
II staining was measured for the DCs from each analyzed sample (Figure 23), giving the median 
expression level of MHC II molecules at the surface of each individual cell. Comparing the two 
genotypes, no difference in MHC II expression was observed on the DCs. 
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Figure 23 Median expression level of MHC II at the surface of DCs in CD4:cre-PHD2
f/f 
in the 5 week 
OVA-induced asthma model. Mean fluorescence intensity of the MHC II molecules at the DCs surface 
was quantified via flow cytometry for both WT-triggered (n=4) and CD4:cre-PHD2
f/f
-triggered mice 
(n=5). Data are presented as mean ± SEM. n.s. – not significant. 
 
Although a similar expression of this molecule at the surface of the DCs exists between 
genotypes, other environmental factors such as cytokine levels in the tissue affect iTreg 
development. The TGF-β signaling is important for the development, survival and function of 
these cells, but also IL-2 and RA lead to the expansion of iTregs30. This last factor is produced 
by a particular subset of DCs expressing CD10329 and therefore the expression of this molecule 
at the surface of the antigen-presenting DCs could be analyzed in the future in order to 
confirm that no differences exist between genotypes in the Ag presentation that leads to 
iTregs.  
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2.1.6. Lung cytokine concentration measurement 
Since CD4+ T cell differentiation showed already a transition in the direction of 
resolution of the inflammatory response, the inflammatory milieu in the tissue originated by a 
previous inflammatory stimulation could be the major factor driving the observed changes in 
the epithelial cells in the lung.  
As the cytokines produced by the Th2 cells, such as IL-4, IL-5 and IL-13 have an 
important role in the recruitment of inflammatory cells and in the remodeling observed in the 
asthmatic tissue6, their concentration was measured in the homogenates from lung tissue 
(Figure 24). 
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Figure 24 Pro-allergic cytokine concentration in the lung in CD4:cre-PHD2
f/f
 in the 5 week OVA-
induced asthma model.  IL-4, IL-5 and IL-13 were quantified in the lung tissue of WT-triggered (n=6-8) 
or CD4:cre-PHD2
f/f
 mice (n=6-10) via ELISA and ECL assays. Data are presented as mean ± SEM. n.s. – not 
significant. 
 
No differences were found between WT and CD4:cre-PHD2f/f mice. A possible 
explanation for the lack of difference between the phentotypes might come from the fact that 
these cells have been triggered for over a week, which might be too long. Shorter time periods 
of eliciting (e.g. 2-3 days) will therefore have to clarify the discrepancy between the observed 
increased mucus production and the comparable pro-allergic milieu observed. 
During asthma, macrophages are differentiated simultaneously into a M2 phenotype 
as well as a M1 subtype36,37. While the first secrete anti-inflammatory cytokines that 
potentiate the Th2 differentiation and eosinophil recruitment as well as lung fibrosis, such as 
IL-13 and TGF-β37; M1 cells secrete pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α, 
which promote activation of fibroblasts in the tissue, leading to the AHR observed in asthma36.  
IL-1β modulates the constriction of the airway SMC directly and promotes the 
activation of fibroblasts, being its production by M1 macrophages associated with a higher 
hyperresponsiveness in the lung with consequent airflow limitation53.  
IL-6 is mainly produced by macrophages, being also released by DCs, B cells and 
epithelial cells. When produced by APCs, this cytokine induces the initial IL-4 production by the 
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Th2 cells55, whereas its production by epithelial cells is associated with an increased stress 
state of these cells and increased mucus secretion56. 
TNF-α is secreted by several cells, including macrophages, T cells, epithelial cells and 
SMC. AMs from asthmatic individuals produce higher concentrations of this mediator under 
IgE stimulation. This cytokine is found in increased amounts in BALF of asthmatic individuals 
and acts directly on the smooth muscle, increasing its contractibility and contributing to the 
observed AHR in the patients36. TNF-α can also activate eosinophils and macrophages, 
inducing the production of IL-1β, IL-6 and TNF-α-itself by the latter57. 
As pro-inflammatory cytokines have a role in the pathogenesis of the disease, their 
levels were quantified via ECL in both WT and CD4:cre-PHD2f/f tissue homogenate. IL-10 was 
also measured, as this anti-inflammatory cytokine produced mainly by M2 macrophages and 
Treg cells inhibits the inflammation in the tissue, prompting the resolution of the asthmatic 
response36 (Figure 25). 
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Figure 25 Pro- and anti-inflammatory cytokine concentration in the lung in CD4:cre-PHD2
f/f
 in the 5 
week OVA-induced asthma model. Pro-inflammatory cytokines IL-1β, IL-6 and TNF-α (A) as well as anti-
inflammatory cytokine IL-10 (B) were quantified in the lung tissue of WT-triggered (n=6) or CD4:cre-
PHD2
f/f
 mice (n=6) via ECL assays. Data are presented as mean ± SEM. n.s. – not significant. 
 
Although a slight tendency was observed for higher concentration of pro-inflammatory 
cytokines in the homogenized lung tissue from the CD4:cre-PHD2f/f mice, no significant 
differences in IL-1β, IL-6 or TNF-α levels were observed between genotypes (Figure 25A).  
The lack of a clear increase in the IL-1β concentration in the CD4:cre-PHD2f/f mice is in 
accordance with the absence of differences between genotypes in collagen deposition 
surrounding the bronchi. The comparable concentration between genotypes of TNF-α also 
correlates with the lack of differences in the levels of the remainder pro-inflammatory 
cytokines analyzed. 
As for IL-6 levels, the slight increase in its concentration observed in the CD4:cre-
PHD2f/f mice, could be due to the higher production of this cytokine by the epithelium and not 
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by the macrophages in the tissue, since the mucus secretion in the bronchi is elevated 
comparing with the WT.  
Regarding the IL-10 concentration, both genotypes express the same level of this 
cytokine in the lung homogenate (Figure 25B), which is not in agreement with the trend for 
higher Treg percentage in the CD4:cre-PHD2f/f mice. However, Treg cells represent only a 
fraction of the IL-10-producing cells in the tissue and the increased production of this cytokine 
by these cells might be insignificant when measuring IL-10 in tissue homogenate.  
The similarity in cytokine concentration between genotypes might be associated with 
the observed transition to a resolution of inflammation in the tissue and, therefore, 
measurement of these mediators at this phase is not elucidatory of the mechanism that drives 
the higher susceptibility of the CD4:cre-PHD2f/f mice to asthma. Differences in the cytokine 
production that ultimately leads to the tissue remodeling in the lung might exist at an earlier 
phase of the response, creating a need for measurement of these mediators in previous time 
points. 
 
 
2.1.7. Serum IgE concentration measurement 
Under normal conditions, IgE exists in minute amounts in circulation. However, during 
an allergic response, Th2 cells induce the Ig class switching of the antibodies produced by the 
B cells into IgE via IL-4 production, leading to the increase of this antibody levels in the blood31.  
This antibody is specific for the antigen used in the triggering of the asthmatic response and 
has long-lived interactions with inflammatory cells such as eosinophils, inducing the 
production of leukotrienes by these cells and therefore contributing for the 
bronchoconstriction in the lung tissue33. IgE concentration was measured in the serum of the 
analyzed mice using ELISA (Figure 26).  
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Figure 26 IgE levels in the serum of CD4:cre-PHD2
f/f
 mice in the 5 week OVA-induced asthma model. 
IgE concentration was measured in the serum of WT-triggered (n=10) and CD4:cre-PHD2
f/f
 mice (n=10). 
Data are presented as mean ± SEM. n.s. – not significant. 
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No differences were observed between genotypes. As IgE stimulation of the AMs in 
the lung leads to the increased production of IL-1β, IL-6 and TNF-α33 the comparable 
concentration of IgE in both WT and CD4:cre-PHD2f/f mice corroborates the lack of difference 
in concentration of these cytokines in the lung tissue. As IgE has a very short half-life in 
circulation, of less than a day31, the measured similar concentration between genotypes might 
be the result of the analogous concentration of IL-4 at the time of analysis.  
Asthma is characterized by an early-phase response which involves the activation and 
infiltration of inflammatory cells in the lung tissue and a late-phase response, which is 
associated with tissue remodeling that leads to the increased mucus production, AHR and 
bronchoconstriction observed in the patients. The aforementioned comparable levels of cells, 
cytokines and mediators between the WT and CD4:cre-PHD2f/f mice might indicate that at the 
analyzed time point these factors have reached a plateau and that the differences in mucus 
production are the outcome of distinct concentrations of these mediators at an earlier time 
point. Therefore, all of the analyzed parameters suggest the reaching of a late-phase response 
in the asthmatic mice. 
 
The 5 week OVA model allowed the characterization of a more extreme asthmatic 
phenotype regarding the Goblet cell metaplasia in the CD4:cre-PHD2f/f mice, which is 
associated with a trend for higher vascular remodeling that hinders the perfusion of the tissue. 
Although no differences in cell infiltration and cytokine concentration were observed between 
the two groups, a tendency for increased conversion of the pro-allergic response into an 
resolution phase exists for the CD4:cre-PHD2f/f mice. This might, thus, be indicative of a late-
phase during the disease and at which point several hallmarks of the disease are severely 
expressed. Unfortunately, this avoids the correct characterization of the mechanism through 
which the differences between genotypes occur. Therefore, a milder model of the disease 
could contribute to the unraveling of the mechanism that modulates the more severe 
phenotype in the CD4 cKO. 
 
 
 
 
 
45 
 
2.2. 2 week OVA-induced Asthma Model 
As the asthma phenotype aggravated in the CD4:cre-PHD2f/f mice compared to WT 
littermates, with extensive vascular remodeling that limits the perfusion of the lung tissue, a 
shorter model was used in order to assess if the difference was also maintained in a milder 
model of airway allergy. 
 
2.2.1. Tissue remodeling evaluation 
Histological analysis was performed to study Goblet cell coverage in the bronchi and 
vascular remodeling in this model, as these were the two major hallmarks altered in the 
CD4:cre-PHD2f/f in the 5 week OVA model (Figures 27 and 28). 
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Figure 27 Goblet cell quantification in lung sections from untreated WT (n=2), WT-triggered (n=5) and 
CD4:cre-PHD2
f/f
-triggered mice (n=5) in the 2 week OVA-triggered asthma model. The percentage of 
bronchi expressing Goblet cells (A) and the overall Goblet cell coverage in the lung (B) were measured. 
Data are presented as mean ± SEM.  n.e. – not expressed; n.s. – not significant; ***p<0.001.  
 
Treatment with OVA in the 2 week model leads to an increase in the percentage of 
bronchi expressing Goblet cells (Figure 27A). This increase is significantly higher in the CD4:cre-
PHD2f/f mice, following a similar trend to what was obtained in the 5 week model. However, 
the Goblet cell coverage in the lung shows no significant differences after triggering, although 
there is a trend for increased coverage in the CD4:cre-PHD2f/f genotype (Figure 27B). This 
tendency resembles the increased Goblet cell coverage observed in the 5 week model and 
might indicate that this model could be used as an alternative to the aforementioned 5 week 
OVA-induced asthma. 
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Regarding the vascular remodeling in the lung tissue after asthmatic triggering, no 
differences between untreated and treated mice were observed (Figure 28). 
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Figure 28 Quantification of the vascular remodeling in the lung in CD4:cre-PHD2
f/f
 in the 2 week OVA-
induced asthma model. Lung sections from untreated WT (n=2), WT-triggered (n=5) and CD4:cre-
PHD2
f/f
-triggered (n=5) were analyzed using ImageJ. Vascular luminal area is expressed as the ratio 
between the lumen area of the vessel and the total area of the vessel. Small vessels depict vessels with 
a total area smaller than 10mm
2
, being the large vessels of sizes above the aforementioned. Data are 
presented as mean ± SEM. n.s. – not significant.  
 
The milder phenotype observed, with no changes in vascular thickening, allowed the 
successful perfusion of the lung tissue of both WT and CD4:cre-PHD2f/f mice affected with 
airway allergy. 
As the tissue remodeling observed in the 2 week OVA-induced asthma follows a 
similar trend to what was observed in the 5 week model with regard to the mucus production, 
this model could be representative of a similar, but milder, response as to what obtained in 
the previous model analyzed. The lack of vascular remodeling allows the perfusion of the lung 
tissue, contributing to a better removal of the blood from the tissue and allowing more 
reliable inflammatory cell quantification in the lung. 
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2.2.2. Inflammatory cell infiltration analysis 
Cell infiltration in the BALF was assessed with flow cytometry in order to study which 
are the main cell populations in this asthma model that might characterize the phenotype 
(Figure 29). 
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Figure 29 Inflammatory cell infltration in the BALF in CD4:cre-PHD2
f/f
 in the 2 week OVA-induced 
asthma model. The total counts of each leukocyte cell population were assessed by flow cytometry in 
the BALF of untreated WT (n=3), WT-triggered (n=9) and CD4:cre-PHD2
f/f
-triggered mice (n=9). Data are 
presented as mean ± SEM. n.s. – not significant.  
 
Upon asthmatic triggering, leukocyte infiltration was observed in the BALF, of mainly T 
cells, particularly CD4+, and neutrophils in the same extent in both genotypes. No significant 
eosinophilia was observed in this model, indicating that the major cells involved in the 
observed tissue remodeling are not the same as in the 5 week model. Infiltration of 
neutrophils into the BALF is not representative of the majority of asthma conditions, which are 
characterized by a high eosinophilia23.  
 
The 2 week OVA-induced asthma model elicits a similar, albeit milder Goblet cell 
coverage to what is obtained with the 5 week OVA-induced asthma model. Interestingly, the 
observed trend pointed to a more severe phenotype in the CD4:cre-PHD2f/f mice in regards of 
this parameter. This milder triggering also has the advantage of not leading to the vascular 
remodeling that represented a hindrance in perfusion of the lung tissue. However, major 
infiltrating cells in this model of the disease are not the eosinophils, but also the neutrophils. 
This outcome is distinct from what occurs in the 5 week OVA-induced model and does not 
resemble the majority of asthma cases, as only a minority of the asthmatic patients has 
neutrophilia associated with their condition23. As this model might not be representative for 
the regular asthmatic phenotype, another short-term airway allergy model was established in 
order to assess the response in both genotypes under conventional asthma. 
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2.3. HDM-induced Asthma Model 
OVA-induced asthma models are widely accepted in the study of this disease, but 
these require a sensitization period in order to elicit the allergy, as mice are not naturally 
allergic to this protein. HDM, however, is a common allergen in humans and induces an 
allergic response in mice without the need of previous sensitization50. As HDM models involve 
less triggering events than the OVA model, they resemble a more natural airway allergy. The 
asthma phenotype was assessed in WT and CD4:cre-PHD2f/f using this allergen. 
 
2.3.1. Tissue remodeling evaluation 
As histological analysis is the most reliable way to assess the asthmatic phenotype, 
PAS staining was performed in sections from both genotypes (Figure 30). 
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Figure 30 Goblet cell quantification in lung sections from WT-triggered (n=2) and CD4:cre-PHD2
f/f
-
triggered mice (n=4) in the HDM-induced asthma model. The percentage of bronchi expressing Goblet 
cells (A) and the overall Goblet cell coverage in the lung (B) were measured. Data are presented as 
mean ± SEM. n.s. – not significant. 
 
Although not significant, there is a trend for higher Goblet cell coverage in the 
CD4:cre-PHD2f/f mice comparing with the WT mice treated with HDM. However, the analyzed 
groups are very small (n=2 for the WT, n=4 for the cKO), being only indicative of a possible 
phenotypic difference between the CD4:cre-PHD2f/f mice and the WT littermates, but not 
allowing to conclude that indeed a higher airway remodeling exists. This could, however, 
indicate that the observed phenotype in the 5 week OVA model is reproducible in the HDM 
model and that this should be further explored to assess other hallmarks of the disease. 
Further experiments will be required to confirm this hypothesis. 
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2.3.2. Inflammatory cell Infiltration analysis 
After induction of the airway allergy with the HDM, there was an influx of leukocytes 
into the BALF, with an influx of mainly eosinophils and T cells (Figure 31). 
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Figure 31 Inflammatory cell infltration in the BALF in CD4:cre-PHD2
f/f
 in the HDM-induced asthma 
model. The total quantification of each leukocyte cell population was assessed by flow cytometry in the 
BALF of untreated WT (n=2), WT-triggered (n=5) and CD4:cre-PHD2
f/f
-triggered mice (n=4). Data are 
presented as mean ± SEM. n.s. – not significant.  
 
Comparing both groups, identical cell infiltration in the BALF was observed. This 
outcome is in agreement to what observed in the 5 week OVA-induced model and confirms 
that cell infiltration in the BALF is not altered in the CD4:cre-PHD2f/f mice.  
 
 
2.3.3. Serum IgE concentration measurement 
Assessing IgE levels in the serum, no differences were obtained between genotypes 
(Figure 32). 
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Figure 32 IgE levels in the serum of CD4:cre-PHD2
f/f
 mice in the HDM-induced asthma model. IgE 
concentration was measured in the serum of WT-triggered (n=5) and CD4:cre-PHD2
f/f
 mice (n=4). Data 
are presented as mean ± SEM. n.s. – not significant.  
 
As IgE production by the B cells is induced by the IL-4 secreted by the activated Th2 
cells upon antigen presentation by the DCs31, the observed similar concentration of this 
antibody in circulation might be an indicator of a comparable IL-4 concentration at the time of 
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analysis and of a similar phenotype to that observed in the 5 week OVA asthma model. Further 
analysis of cytokine levels in the tissue, as well as Th cell differentiation should be performed 
to confirm this hypothesis.   
 
Albeit the fact that in either studied asthma models no differences in cell infiltration 
and in several mediators are observed, there is a trend for a harsher phenotype in the 
CD4:cre-PHD2f/f asthmatic mice for both a 5 week OVA-induced asthma model and an HDM-
induced asthma model. This outcome is indicative of a higher susceptibility for airway allergy 
in the CD4:cre-PHD2f/f mice, suggesting that PHD2 might have a protective role in the T cells 
during asthma. 
 
 
3. The Role of PHD2 and PHD3 in Myeloid cells 
during Asthma 
All three PHD family members can hydroxylate and consequently inactivate HIFα. 
However, PHD2 has been described as the major HIF prolyl hydroxylase, as its inactivation with 
specific small interfering RNA (siRNA) is sufficient for the robust induction of HIFα in spite of 
the presence of PHD1 and PHD317. Nevertheless, deletion of either PHD1 or PHD3 in 
conjunction with PHD2 leads to the modulation of the HIF response in distinct manners, 
having a compensatory effect upon hypoxia conditions in the protection against continued 
lack of oxygen. PHD3 was described as a HIF1α target, being its transcription markedly induced 
under hypoxic conditions. This protein has a very potent role in the negative regulation of 
HIF2α15. Therefore, PHD3 represents a link between HIF1α and HIF2α, maintaining a tight 
balance between the activation of these two transcription factors20, and being involved in a 
feedback loop to suppress HIF activation under prolonged hypoxia19. 
As the mice with deletion of PHD2 in the myeloid compartment did not shown a higher 
susceptibility to the airway allergy in a 5 week OVA-induced model, a possible protective role 
of HIF1α through the upregulation of PHD3 and consequent inhibition of HIF2α in these cells 
was considered.  To assess the role of the ensuing PHD3 activation in these cells, LysM:cre-
PHD2f/f PHD3f/f were submitted to a 5 week OVA model of airway allergy. 
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3.1. Inflammatory cell Infiltration Analysis 
Cell infiltration in the BALF of both WT and LysM:cre-PHD2f/f PHD3f/f triggered mice 
was analyzed through flow cytometry. As one of the three performed experiments elicited a 
higher cell infiltration in all mice, which could be due to other environmental factors at the 
time of the experiment, cell infiltration is represented as a relative amount in comparison with 
the average of each individual WT groups (Figure 33). 
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Figure 33 Inflammatory cell infiltration in the BALF of LysM:cre-PHD2
f/f
 PHD3
f/f
 mice in the 5 week 
OVA-induced asthma model. The percentage (A) or relative counts (B) of each leukocyte cell population 
were assessed by flow cytometry in the BALF of WT-triggered (n=11) and LysM:cre-PHD2
f/f 
PHD3
f/f
-
triggered mice (n=8). In (B) the average of each WT group in each individual experiment was set to 
100%, being the cell numbers in the cKO represented in relation to this value. Data are presented as 
mean ± SEM. n.s. – not significant; *p<0.05; **p<0.01. 
 
Interestingly, contrary to what was observed in the CD4:cre-PHD2f/f mice, the 
LysM:cre-PHD2f/f PHD3f/f mice showed a higher cell infiltration in the BALF comparing to the 
OVA-triggered WT. This difference was mainly due to higher CD4+ T cell and eosinophil 
numbers in this fluid. The increased number of these cells was observed in every individual 
experiment and could indicate a more severe asthma phenotype in these mice, as CD4+T cells 
and eosinophils modulate the majority of downstream effects observed in this disease6.  
To assess if a higher severity of the asthmatic phenotype is present in these mice, 
parameters such as cytokine production, IgE in circulation and tissue remodeling were 
analyzed. 
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3.2. Lung Cytokine Concentration Measurement 
Comparing Th2 cytokine levels in the analyzed mice, no differences were observed 
(Figure 34). 
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Figure 34 Pro-allergic cytokine concentration in the lung in the LysM:cre-PHD2
f/f
 PHD3
f/f
 mice. IL-4, IL-
5 and IL-13 were quantified in the lung tissue of WT-triggered (n=6) or LysM:cre-PHD2
f/f
 PHD3
f/f
 mice 
(n=6) via ELISA and ECL assays. Data are presented as mean ± SEM. n.s. – not significant. 
 
LysM:cre-PHD2f/f PHD3f/f mice showed increased cell infiltration in the BALF, mainly of 
CD4+ T cells and eosinophils. The latter are attracted to the lung by the production of eotaxin 
by the Th2 cells25 and therefore a higher pro-allergic cytokine concentration was expected. The 
observed similarity in cytokine production could indicate that, at the analyzed time point, 
production of these cytokines by the Th2 cells has yet to occur. Therefore, after four days of 
triggering cells might be still at a point of initial migration into the tissue. 
Analyzing the pro-inflammatory cytokines in the tissue, there was a trend for reduced 
levels in the LysM:cre-PHD2f/f PHD3f/f mice compared to WT littermates (Figure 35A). Although 
these cytokines contribute to the airway remodeling in the tissue, they inhibit the 
differentiation of T cells into the Th2 subset and might therefore be detrimental to the 
recruitment and activation of this subset.  
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Figure 35 Pro- and anti-inflammatory cytokine concentration in the lung of LysM:cre-PHD2
f/f
 PHD3
f/f
 
mice. Pro-inflammatory cytokines IL-1β, IL-6 and TNF-α (A) as well as anti-inflammatory cytokine IL-10 
(B) were quantified in the lung tissue of WT-triggered (n=6) or LysM:cre-PHD2
f/f
 PHD3
f/f
 mice (n=6) via 
ECL assays. Data are presented as mean ± SEM. n.s. – not significant. 
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The lower concentration of pro-inflammatory cytokines could be indicative of lower 
differentiation of the macrophages into a M1 phenotype due to a higher M2 differentiation by 
these cells and, therefore, the establishment of an environment more prone to Th2 
differentiation. As modulation of PHD2 and PHD3 in these mice is done at a myeloid cell level, 
affecting some cells at the first line of defense in the tissue, it might be that in these mice the 
asthmatic response is still in an early phase at the analyzed time point. Measurement of TGF-β 
levels in these mice could give further insight regarding the differentiation of the macrophages 
in the LysM:cre-PHD2f/f PHD3f/f mice. Regarding the IL-10 concentration (Figure 35B), no 
differences between the groups were observed. If the asthmatic response in these mice is still 
at an early phase during the point of analysis, the production of this cytokine might still be 
inhibited by the inflammatory cells that are present in the tissue, which could explain the 
comparable observed concentration between genotypes.  
3.3. Serum IgE Concentration Measurement 
A slight trend for higher concentration of IgE in circulation was observed for the 
LysM:cre-PHD2f/f PHD3f/f mice, albeit not significant (Figure 36). 
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Figure 36 IgE levels in the serum of LysM:cre-PHD2
f/f
 PHD3
f/f
 asthmatic mice in the 5 week OVA-
induced asthma model. IgE concentration was measured in the serum of WT-triggered (n=6) and 
LysM:cre-PHD2
f/f
 PHD3
f/f
 mice (n=6). Data are presented as mean ± SEM. n.s. – not significant. 
 
IgE is produced under stimulation of the B cells by the activated Th2 cells and induces 
the further generation of this CD4+T cell subset in the lymph nodes when bound to the surface 
of DCs31. This antibody also stimulates leukotriene production by the eosinophils in the lung33, 
and its mild increase in the LysM:cre-PHD2f/f PHD3f/f might be consistent with a higher 
eosinophil activity in the lung and, therefore, of a harsher phenotype of the disease. 
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3.4. Tissue Remodeling Evaluation 
To assess the tissue remodeling in these mice after asthmatic triggering, Goblet cell 
coverage was analyzed for both OVA-treated WT and LysM:cre-PHD2f/f PHD3f/f (Figure 37). 
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Figure 37 Goblet cell quantification in lung sections from WT-triggered (n=6) and LysM:cre-PHD2
f/f
 
PHD3
f/f
-triggered mice (n=6). The percentage of bronchi expressing Goblet cells (A) and the overall 
Goblet cell coverage in the lung (B) were measured. Data are presented as mean ± SEM. n.s. – not 
significant. 
 
Although the cell infiltration in the BALF and proinflammatory cytokine levels in the 
lung tissue seem to be in agreement with an induction of the Th2 differentiation and, 
therefore, a harsher asthma phenotype in the LysM: cre PHD2f/f PHD3f/f, the Goblet cell 
occupation in the bronchi is comparable to what observed in the WT asthmatic mice. Neither 
the percentage of Goblet cell-expressing bronchi (Figure 33A) nor the overall coverage of 
these cells (Figure 33B) was altered in the cKO mice. 
As the modulation of PHD2 and PHD3 in these mice occurs in the myeloid 
compartment, affecting macrophages, myeloid-derived DCs and possibly eosinophils and 
neutrophils, the changes caused by the deletion of these proteins might interfere with an 
initial step in asthma. Therefore, the analyzed time point might represent an initial stage of 
the disease in this genotype. Additional triggering and later analysis of these mice should be 
done to further describe the asthmatic response and overall phenotype in these mice. 
Nevertheless, the higher infiltration of CD4+ T cells and eosinophils in the BALF of the 
LysM:cre-PHD2f/f PHD3f/f mice suggests that the migration of these cells to the area of damage 
is enhanced and might contribute for a more severe phenotype which might not be reflected 
in the remodeling of the tissue. Future work needs to be done to assess if HIF1α activation in 
the myeloid cells has a protective role through the activation of PHD3 and consequent 
inhibition of HIF2α. 
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Conclusions and Future Work 
The hypoxic environment established upon asthmatic triggering contributes to the 
increased cell infiltration and tissue damage observed in asthmatic patients, leading to 
dyspnea, AHR and sputum production. Although systemic inhibition of the hypoxia pathway 
has been shown to reduce the disease outcome7,21, little is known about the role of this 
pathway in the inflammatory cells involved in the development of asthma. 
The study of the role of oxygen sensors in inflammatory diseases is currently 
widespread and well established, allowing the modulation of these proteins in individual cell 
types. As T cells and myeloid cells have a significant role in the pathogenesis of asthma, 
modulating the hypoxia response in these cells might shed light on the particular aspects of 
this pathway in these cells. 
In a model of OVA-induced lung inflammation, PHD2-deficiency in the T cell 
compartment of mice (CD4:cre-PHD2f/f) leads to a higher mucus production by the epithelial 
cells in the bronchus. This higher secretion seems to be mediated by metaplasia but not 
hyperplasia of the epithelial cells into Goblet cells. Although no differences between 
genotypes are apparent in collagen deposition surrounding the bronchi, the higher mucus 
production by the CD4:cre-PHD2f/f bronchi, as well as higher vascular remodeling in the lung is 
an indicator of a more severe asthmatic phenotype. This mucus production phenotype is 
observed for the 5 week OVA-induced asthma model as well as the HDM-induced asthma 
model. This strongly suggests that there is indeed a higher susceptibility of the CD4:cre-PHD2f/f 
mice to the asthmatic condition.  
Lung tissue remodeling is the outcome of an inflammatory milieu and of the signaling 
of pro-allergic and pro-inflammatory cytokines. The lack of difference in the levels of these 
mediators between mice lacking PHD2 in the T cells and their WT littermates is counter-
intuitive considering the overall outcome of the disease. However, this might arise from the 
fact that in both genotypes the concentration of this cytokines might plateau after four days of 
asthmatic triggering. Indeed, CD4+ T cells at this time point show a conversion from a Th2 
phenotype, majorly involved in the pathogenesis of asthma, to a Treg phenotype that 
suppresses the inflammatory response and might represent the initiation of the resolution of 
inflammation51,52. 
To unravel the mechanism that leads to the observed higher sensitivity in the CD4:cre-
PHD2f/f mice, future studies need to focus on the analysis of a time point preceding the one 
analyzed in this work. Cell infiltration, as well as IgE in circulation and cytokine levels in the 
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tissue should be assessed, as these factors are the major contributors to the early-phase 
response that occurs in asthma. qPCR or ELISAs on cell pellet from fluorescence-activated 
sorted cells will contribute to the identification of the cells involved in the production of the 
mediators that contribute to the disease outcome. CD4+ T cell differentiation during this 
period needs also to be studied, as this mechanism seems to be altered at a later time point. In 
vitro recall assays will be performed to facilitate the study of the potential differentiation of 
these cells under stimulation of the antigen. The combination of all these approaches will 
allow a further understanding of the protective role of PHD2 in the T cells during asthma. 
A mouse strain lacking PHD2 and PHD3 in the T cell compartment (CD4:cre-PHD2f/f 
PHD3f/f) is currently being established. As deletion of both oxygen sensors in the myeloid 
compartment (LysM:cre-PHD2f/fPHD3f/f) reveals an expansion of the sensitivity window, with 
delayed inflammatory response in the lung tissue upon asthma triggering, the induction of 
airway allergy in CD4:cre-PHD2f/f PHD3f/f might elicit a similar outcome. Future studies will 
therefore focus on the analysis of the feedback mechanism between PHD2 and PHD3 in the T 
cell compartment and its influence in the asthmatic outcome. 
 
PHD3 is involved in a feedback loop to suppress HIF, particularly HIF2α, under 
prolonged hypoxia. The induction of the transcription of this protein during HIF1α induction 
might have a protective role during asthma. Indeed, the results obtained in this work 
demonstrate that deletion of both PHD2 and PHD3 in the myeloid compartment contributes to 
a higher cell infiltration in the BALF during asthma, with a marked influx of CD4+ T cells and 
eosinophils, the major intervenient cells in this disease. Albeit the higher cell influx, no 
increase in mucus production could be revealed in the LysM:cre-PHD2f/f PHD3f/f mice versus 
their WT littermates. This, associated with the trend for reduced pro-inflammatory cytokine 
levels in the lung tissue, might suggest that the mice were evaluated during the initial phase of 
the disease, indicated by the infiltration of the cells in the lung and establishment of a 
propitious environment for the differentiation of CD4+ T cells into a Th2 phenotype. 
Future studies need to assess this question by measuring cell infiltration, tissue 
remodeling and cytokine concentration in the lung tissue at later time points, as four days of 
triggering might be insufficient to observe the effect of the PHD2 and PHD3 deletion in the 
myeloid cells in the pathology of asthma. As the modulation of the aforementioned PHDs 
occurs in the monocytes, macrophages, as well as myeloid-derived DCs, the activation and 
recruitment of T cells might be altered in these mice. In vitro co-culture of allergen-pulsed DCs 
from LysM:cre-PHD2f/f PHD3f/f mice with WT T cells or adaptive transfer of these cells into 
naïve mice might help elucidate the mechanisms involved in this recruitment. Also, similar 
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studies need to be performed to analyze the capacity of the pulmonary macrophages to inhibit 
the DCs activation and migration to the lymph nodes.  
Overall, this work has described for the first time a protective role of PHD2 in the T 
cells during asthma, indicating also a possible role for PHD3 in the myeloid compartment in 
the control of this disease. Further study of the mechanism of both models might contribute 
to the development of novel therapies and therefore a better management of a yet to be 
controlled disease. 
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Appendix 
 
Figure 38 Myeloid staining gating strategy.  
 
 
 
Figure 39 Lymphoid staining gating strategy.  
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Figure 40 Lymph node staining gating strategy. 
